US20210137826A1 - Use of chenopodium formosanum (djulis) extract for antioxidation and improving skin appearance - Google Patents
Use of chenopodium formosanum (djulis) extract for antioxidation and improving skin appearance Download PDFInfo
- Publication number
- US20210137826A1 US20210137826A1 US17/095,763 US202017095763A US2021137826A1 US 20210137826 A1 US20210137826 A1 US 20210137826A1 US 202017095763 A US202017095763 A US 202017095763A US 2021137826 A1 US2021137826 A1 US 2021137826A1
- Authority
- US
- United States
- Prior art keywords
- extract
- skin
- djulis
- red quinoa
- chenopodium formosanum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000284 extract Substances 0.000 title claims abstract description 137
- 241001191531 Chenopodium formosanum Species 0.000 title claims abstract description 26
- 230000003064 anti-oxidating effect Effects 0.000 title description 16
- 230000037075 skin appearance Effects 0.000 title description 2
- 239000003125 aqueous solvent Substances 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims description 81
- 210000003491 skin Anatomy 0.000 claims description 78
- 210000004027 cell Anatomy 0.000 claims description 43
- 108090000623 proteins and genes Proteins 0.000 claims description 41
- 239000000203 mixture Substances 0.000 claims description 40
- 230000014509 gene expression Effects 0.000 claims description 33
- 235000013305 food Nutrition 0.000 claims description 12
- 230000003020 moisturizing effect Effects 0.000 claims description 12
- 235000013824 polyphenols Nutrition 0.000 claims description 12
- 229930003935 flavonoid Natural products 0.000 claims description 11
- 150000002215 flavonoids Chemical class 0.000 claims description 11
- 235000017173 flavonoids Nutrition 0.000 claims description 11
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 11
- 230000002087 whitening effect Effects 0.000 claims description 11
- 230000008099 melanin synthesis Effects 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 210000004927 skin cell Anatomy 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 6
- 235000013402 health food Nutrition 0.000 claims description 4
- 239000002537 cosmetic Substances 0.000 claims 3
- 230000002000 scavenging effect Effects 0.000 claims 1
- 230000036548 skin texture Effects 0.000 abstract description 16
- 230000037067 skin hydration Effects 0.000 abstract description 15
- 238000007254 oxidation reaction Methods 0.000 abstract description 5
- 230000037303 wrinkles Effects 0.000 abstract description 5
- 230000003647 oxidation Effects 0.000 abstract description 4
- 240000006162 Chenopodium quinoa Species 0.000 description 147
- 239000000243 solution Substances 0.000 description 39
- 238000002474 experimental method Methods 0.000 description 30
- 230000003078 antioxidant effect Effects 0.000 description 25
- 102000004190 Enzymes Human genes 0.000 description 23
- 108090000790 Enzymes Proteins 0.000 description 23
- 229940088598 enzyme Drugs 0.000 description 23
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 21
- 239000003963 antioxidant agent Substances 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 21
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 239000000463 material Substances 0.000 description 20
- 239000000902 placebo Substances 0.000 description 20
- 229940068196 placebo Drugs 0.000 description 20
- 238000012360 testing method Methods 0.000 description 20
- 238000002835 absorbance Methods 0.000 description 17
- 206010040954 Skin wrinkling Diseases 0.000 description 16
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 15
- 239000002953 phosphate buffered saline Substances 0.000 description 15
- 239000000523 sample Substances 0.000 description 15
- 102000003425 Tyrosinase Human genes 0.000 description 14
- 108060008724 Tyrosinase Proteins 0.000 description 14
- 238000001914 filtration Methods 0.000 description 14
- 102000016938 Catalase Human genes 0.000 description 13
- 108010053835 Catalase Proteins 0.000 description 13
- 238000010438 heat treatment Methods 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 235000013361 beverage Nutrition 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 235000006708 antioxidants Nutrition 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 10
- 101150058971 KRT10 gene Proteins 0.000 description 9
- 101150056422 Krt1 gene Proteins 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 150000003254 radicals Chemical class 0.000 description 9
- 102100034343 Integrase Human genes 0.000 description 8
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 150000007524 organic acids Chemical class 0.000 description 8
- 101150005399 sod2 gene Proteins 0.000 description 8
- 239000012086 standard solution Substances 0.000 description 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
- 235000015165 citric acid Nutrition 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 7
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 241000209094 Oryza Species 0.000 description 6
- 235000007164 Oryza sativa Nutrition 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 101150039702 TGM1 gene Proteins 0.000 description 6
- 239000007640 basal medium Substances 0.000 description 6
- 238000011088 calibration curve Methods 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000036564 melanin content Effects 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- 235000009566 rice Nutrition 0.000 description 6
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 238000010802 RNA extraction kit Methods 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 230000034659 glycolysis Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 101150040052 KRT14 gene Proteins 0.000 description 4
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 4
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 101150055766 cat gene Proteins 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 239000012737 fresh medium Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 101150062190 sod1 gene Proteins 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 235000004515 gallic acid Nutrition 0.000 description 3
- 229940074391 gallic acid Drugs 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 210000002752 melanocyte Anatomy 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 238000000053 physical method Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 3
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 3
- 235000005493 rutin Nutrition 0.000 description 3
- 229960004555 rutoside Drugs 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229940054269 sodium pyruvate Drugs 0.000 description 3
- -1 superoxide anions Chemical class 0.000 description 3
- 101150023847 tbp gene Proteins 0.000 description 3
- BNGXYYYYKUGPPF-UHFFFAOYSA-M (3-methylphenyl)methyl-triphenylphosphanium;chloride Chemical compound [Cl-].CC1=CC=CC(C[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 BNGXYYYYKUGPPF-UHFFFAOYSA-M 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical compound OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- XKZQKPRCPNGNFR-UHFFFAOYSA-N 2-(3-hydroxyphenyl)phenol Chemical compound OC1=CC=CC(C=2C(=CC=CC=2)O)=C1 XKZQKPRCPNGNFR-UHFFFAOYSA-N 0.000 description 2
- 239000004382 Amylase Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 2
- 102100022624 Glucoamylase Human genes 0.000 description 2
- 101000653497 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) TATA-box-binding protein F Proteins 0.000 description 2
- 102100023970 Keratin, type I cytoskeletal 10 Human genes 0.000 description 2
- 102100040445 Keratin, type I cytoskeletal 14 Human genes 0.000 description 2
- 102100022905 Keratin, type II cytoskeletal 1 Human genes 0.000 description 2
- 108010070514 Keratin-1 Proteins 0.000 description 2
- 108010065038 Keratin-10 Proteins 0.000 description 2
- 108010066321 Keratin-14 Proteins 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 235000015197 apple juice Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000005282 brightening Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000009194 citrus pectin Substances 0.000 description 2
- 229940040387 citrus pectin Drugs 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000002731 protein assay Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- MLIWQXBKMZNZNF-KUHOPJCQSA-N (2e)-2,6-bis[(4-azidophenyl)methylidene]-4-methylcyclohexan-1-one Chemical compound O=C1\C(=C\C=2C=CC(=CC=2)N=[N+]=[N-])CC(C)CC1=CC1=CC=C(N=[N+]=[N-])C=C1 MLIWQXBKMZNZNF-KUHOPJCQSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 description 1
- 238000008998 Catalase assay kit Methods 0.000 description 1
- 241000871189 Chenopodiaceae Species 0.000 description 1
- 241000219312 Chenopodium Species 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000614436 Homo sapiens Keratin, type I cytoskeletal 14 Proteins 0.000 description 1
- 241000519695 Ilex integra Species 0.000 description 1
- 108010028688 Isoamylase Proteins 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- 241000724182 Macron Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 235000020937 fasting conditions Nutrition 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 102000034240 fibrous proteins Human genes 0.000 description 1
- 108091005899 fibrous proteins Proteins 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- MVDDKFXFPMDCSM-UHFFFAOYSA-N formaldehyde;hydrogen peroxide Chemical compound O=C.OO MVDDKFXFPMDCSM-UHFFFAOYSA-N 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 235000021189 garnishes Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 150000004680 hydrogen peroxides Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000003963 intermediate filament Anatomy 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000012459 muffins Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001007 puffing effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 238000003156 radioimmunoprecipitation Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 210000004511 skin melanocyte Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 108010058734 transglutaminase 1 Proteins 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 101150022728 tyr gene Proteins 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Definitions
- the present invention relates to a use of Chenopodium formosanum ( Djulis ) extract, particularly to the use of Chenopodium formosanum ( Djulis ) extract for the use of antioxidation and improving skin appearance, including skin moisturizing, skin whitening, and skin wrinkle smoothing.
- Chenopodium formosanum also known as Taiwan quinoa, red quinoa, purple quinoa, and rainbow rice, is an annual herb and an endemic species found in Taiwan. It is a close relative of quinoa and belongs to the Chenopodiaceae family and the genus Chenopodium . Distributed in the middle and low altitude mountain areas of central and southern Taiwan, it has more than a hundred years in aboriginal farming history. At present, the aboriginal tribe of Paiwan in Eastern Taiwan has the most abundant seed resources. Red quinoa is edible, and its seedlings, tender stems, and flower spikes can be added to cooking or boiling soup. Red quinoa seeds can also be ground into a powder to serve as raw materials for glutinous rice balls.
- red quinoa The protein content of red quinoa is twice that of rice.
- the fruit of red quinoa is often dried, hulled, and mixed with other grains to serve as general edible rice.
- different processing methods steaming, microwave, roasting, frying, and puffing
- Red quinoa can serve as a garnish for plating and provide rich nutritional value, and is gradually being loved by more and more consumers.
- the present invention discloses a red quinoa extract for improving skin conditions.
- the composition can be used as an antioxidant or for skin whitening and skin moisturizing purposes.
- the red quinoa extract scavenges free radicals in cells, wherein the red quinoa extract is extracted with an aqueous solvent.
- the cell is a skin cell.
- the red quinoa extract achieves the antioxidant effect by enhancing the expression level of antioxidant-related genes.
- the antioxidant-related genes include at least one of the SOD1 gene, the SOD2 gene, or the CAT gene.
- the red quinoa extract achieves the antioxidant effect by increasing the abundance of antioxidant enzymes in a body.
- the Degrees Brix value of the red quinoa extract is 7.0 ⁇ 5.
- the red quinoa extract is used to prepare a composition for improving skin condition, wherein the red quinoa extract is extracted with an aqueous solvent.
- the red quinoa extract is used to prepare a skin whitening composition, wherein the red quinoa extract is extracted with an aqueous solvent.
- the red quinoa extract achieves the skin whitening effect by inhibiting tyrosinase activity and/or reducing the amount of melanin production.
- the red quinoa extract is used to prepare a skin moisturizing composition, and the red quinoa extract is extracted with an aqueous solvent.
- the red quinoa extract achieves the skin's moisturizing effect by enhancing the expression of skin moisturizing-related genes.
- skin moisturizing-related genes include at least one of the TGM1 gene, the KRT1 gene, the KRT10 gene, and the KRT14 gene.
- the aqueous solvent is water or a solvent containing organic acids. In some embodiments, the concentration of the organic acid is 0.05%-1.00%.
- the red quinoa extract is formed by first extracting red quinoa with an aqueous solvent and then undergoing glycolysis using a saccharification enzyme.
- the red quinoa extract of any embodiment can be used to prepare an antioxidant composition.
- the red quinoa extract of any embodiment can be used to prepare a composition that improves the expression of antioxidant-related genes (such as the SOD1 gene, the SOD2 gene, or the CAT gene) in cells.
- the red quinoa extract of any embodiment can be used to prepare a composition for enhancing antioxidant enzymes in the body.
- the red quinoa extract of any embodiment can be used to prepare a skin moisturizing composition.
- the red quinoa extract of any embodiment can be used to prepare a composition that improves the expression of moisturizing-related genes (such as the TGM1 gene, the KRT1 gene, the KRT10 gene, the KRT14 gene) in cells.
- the red quinoa extract of any embodiment can be used to prepare a skin whitening composition.
- the red quinoa extract of any embodiment can be used to prepare a composition that inhibits tyrosine expression.
- the red quinoa extract of any embodiment can be used to prepare a composition that inhibits melanin formation.
- FIG. 1 shows an embodiment of a method for preparing red quinoa extract.
- FIG. 2 shows another embodiment of a method for preparing red quinoa extract.
- FIG. 3 shows the tyrosine inhibition ratios of the experimental and control groups in EXAMPLE 4.
- FIG. 4 shows the melanin production ratios of the experimental and control groups in EXAMPLE 5.
- FIG. 5 shows the gene expression ratios of the antioxidant-related genes in the experimental and control groups in EXAMPLE 6.
- FIG. 6 shows the gene expression ratios of the moisturizing-related genes in the experimental and control groups in EXAMPLE 7.
- FIG. 7 shows skin moisture retention ratios of the experimental and placebo groups in EXAMPLE 8 after intake of health drinks with and without the red quinoa extract, respectively, for 4 weeks and 8 weeks.
- FIG. 8 shows skin whiteness ratios of the experimental and placebo groups in EXAMPLE 8 after intake of health drinks with and without the red quinoa extract, respectively, for 4 weeks and 8 weeks.
- FIG. 9 shows skin texture ratios of the experimental and placebo groups in EXAMPLE 8 after intake of health drinks with and without the red quinoa extract, respectively, for 4 weeks and 8 weeks.
- FIG. 10 shows crow's feet proportions of the experimental and placebo groups in EXAMPLE 8 after intake of health drinks with and without the red quinoa extract, respectively, for 4 weeks and 8 weeks.
- FIG. 11 shows the amount of antioxidant enzyme present in the bodies of the experimental and placebo groups in EXAMPLE 8 after intake of health drinks with and without the red quinoa extract, respectively, for 4 weeks and 8 weeks.
- Microsoft's Excel software is used for statistical analysis in the present invention.
- the data are expressed as mean ⁇ standard deviation (SD), and the differences between groups are analyzed by student's t-test.
- SD standard deviation
- “*” represents a p-value smaller than 0.05
- “**” represents a p-value smaller than 0.01
- “***” represents a p-value smaller than 0.001. The more “*”'s are present, the more significant is the statistical difference.
- the numerical values used in this article are approximate, and all experimental data all include a margin of error of 10%. In some embodiments, the margin of error is 5%.
- wt % refers to percentage by weight
- vol % refers to percentage by volume
- extract refers to a product prepared through extraction.
- the extract can be presented in the form of a liquid solution or a form of a concentrate or essence containing no or little solvent.
- raw red quinoa material generally refers to the plant's seeds, wherein the seeds may include fresh red quinoa, dried red quinoa, or red quinoa processed by other physical methods.
- the physical methods may include chopping, dicing, or crushing. Any physical process that renders the seed different from its original physical property is considered a physical method.
- the red quinoa extract is extracted from raw red quinoa material with an aqueous solvent.
- the red quinoa ( Chenopodium formosanum ( Djulis )) extract is obtained by sequentially performing the crushing procedure S 01 , heating procedure S 02 , filtering procedure S 04 , and concentrating procedure S 06 .
- the raw red quinoa material is hulled red quinoa seeds.
- the red quinoa raw material may be fresh or dried red quinoa seeds.
- the crushing procedure S 01 refers to grinding or crushing the raw red quinoa material until it becomes powdered raw red quinoa material.
- a juicer, a blender, or a homogenizer can be used to perform the crushing procedure 01 .
- the heating procedure S 02 refers to mixing powdered raw red quinoa material with an aqueous solvent and heating it for a fixed period.
- heating refers to increasing the raw red quinoa material's temperature and its aqueous solvent to 50° C. to 100° C.
- a fixed period of time refers to 0.5 hours to 3 hours.
- An example of an embodiment is mixing the powdered raw red quinoa material with an aqueous solvent and increasing the temperature of the solution to 85° C. and maintaining such temperature for 1 hour.
- the weight ratio of the aqueous solvent to the raw red quinoa material ranges from is 5:1-20:1.
- the weight ratio of the aqueous solvent to the raw red quinoa material can be 10:1.
- the aqueous solvent is water or a water solvent containing organic acids.
- the concentration of the organic acid is 0.05% to 1.00%.
- the organic acid and its concentration are at an edible state.
- the organic acid may be citric acid, malic acid, tartaric acid, lactic acid, gluconic acid, acetic acid, but is not limited thereto.
- An example of an embodiment is mixing 90 kg of raw red quinoa material with 900 kg of water and 0.63 kg of citric acid, heating them to 100° C. and maintaining them at 100° C. for 0.5 hours.
- Another example is mixing 90 kg of raw red quinoa material with 900 kg of water and 0.7 kg of citric acid and then heating them to 85° C. and maintaining 85° C. for 1 hour.
- the filtering procedure S 04 refers to passing the heated (or cooled) raw red quinoa material and the aqueous solvent through a filter to filter out the solids or large particles in the solvent to form a filtrate.
- the filter is a 400-mesh filter.
- the cooling process S 03 refers to cooling the processed raw red quinoa materials and its aqueous solvent to room temperature.
- the concentrating procedure S 06 refers to obtaining a first filtrate by concentrating the filtrate obtained from the filtering procedure S 04 under reduced pressure (brand/model: BUCHI-Rotavapor R-100).
- the first extract is the red quinoa extract.
- the concentrating procedure S 06 provides an environment of 40° C. ⁇ 70° C. with reduced atmospheric pressure for concentrating.
- An example of an embodiment of the red quinoa extract is obtained by first crushing raw red quinoa material into powder through the crushing procedure S 01 , then undergoing the heating procedure S 02 , the filtering procedure, and the concentrating procedures S 06 .
- a glycolysis procedure S 05 between the filtering procedure S 04 and the concentrating procedure S 06 is a glycolyzing procedure S 05 .
- a glycolysis enzyme is added to, stirred with, and mixed with the filtrate obtained from the filtering procedure S 04 and then allowed to stand for at least 1 hour to give a glycolyzed solution.
- Glycolysis enzymes further enhance the effect of bioactive ingredients in the red quinoa extract.
- the glycolysis enzymes may be ⁇ -amylase, [beta]-amylase, glucoamylase, isoamylase, or a mixture of at least one.
- the glycolysis enzymes may be glucose amylase (glucan 1,4-alpha-glucosidase).
- the filtrate obtained from the filtering procedure S 04 is added with a 0.06% amount of starch saccharification enzymes.
- the S 05 glycolyzing procedure includes adding a 0.06% amount of a starch saccharification enzyme to the filtrate obtained from the filtering procedure 04 and then heated to and maintained at 55° C. maintained for more than 1 hour to obtain a glycolyzed solution.
- the S 06 concentrating procedure concentrates the glycolyzed solution obtained from the glycolyzed solution S 05 with reduced atmospheric pressure.
- the second filtering procedure S 07 refers to passing the glycolyzed solution obtained by the glycolyzing procedure S 06 through a 400-mesh filter to obtain the red quinoa extract.
- An example of an embodiment of red quinoa extract is obtained by sequentially going through the crushing procedure S 01 , the heating procedure S 02 , the filtering procedure S 04 , the glycolyzing procedure S 05 , the concentrating procedure S 07 , and the second filtering procedure S 07 .
- the red quinoa extract is used to prepare an antioxidant composition, wherein the red quinoa extract achieves the antioxidating effect by promoting the expression of genes related to antioxidation, and wherein the red quinoa extract is extracted with an aqueous solvent. In some embodiments, the red quinoa extract achieves the antioxidating effect by increasing antioxidant enzymes in a body.
- antioxidation refers to the slowing down of or the prevention of oxidation.
- Oxidation refers to a chemical reaction in which one or more elections are transferred from one matter to another. This chemical reaction may generate a radical species and consequently start a chain reaction. When a chain reaction occurs in a cell, the cell will be susceptible to damage or apoptosis.
- the red quinoa extract removes free radicals, terminate the chain reaction, or inhibits other oxidation reactions.
- the radical species in a cell are generated due to light, chemicals, or the natural process of aging.
- the antioxidant-related genes include at least one of the SOD1 gene (GeneID: 6647), the SOD2 gene (GeneID: 6648), or the CAT gene (GeneID: 847).
- the red quinoa extract effectively enhances cellular antioxidation capacity, improves cellular resistance to free radicals, thus protecting skin cells and improving skin condition.
- a concentration of 2 mg/mL of red quinoa extract promotes expression levels of antioxidation-related genes, removes free radicals, and increases cellular antioxidation capacity.
- a red quinoa extract having a Degrees Brix of 7.0 or more improves the expression levels of antioxidation-related genes, removes free radicals, and increases cellular antioxidation capacity.
- a red quinoa extract is used to prepare a skin whitening or brightening composition, wherein the red quinoa extract is achieved the skin whitening or brightening by inhibiting melanin production or inhibiting tyrosine production, wherein the red quinoa extract obtained from an aqueous solvent.
- Tyrosinase is a rate determine enzyme that regulates melanogenesis. Specifically, tyrosinase is involved in two reactions during melanin synthesis: (1) the conversion of a phenolic hydroxyl group into a single diphenol, (2) the oxidation of diphenols to quinones. The enzyme tyrosinase is present in skin melanocytes and is encoded in the TYR gene.
- the red quinoa extract suppresses tyrosinase formation to inhibit, prevent, or slow down melanin production in the skin, which in turn whitens or brightens the skin.
- a concentration of 1 mg/mL of red quinoa extract is used to whiten and brighten skin.
- red quinoa extract with a Degrees Brix of 7.0 or more is used to whiten and brighten skin.
- the red quinoa extract is used to prepare a skin moisturizing composition, wherein the red quinoa extract is extracted with an aqueous solvent, and wherein the red quinoa extract s extracted quinoa through ascension the amount of moisture associated gene expression to achieve the effect of moisturizing the skin.
- moisture-related genes include the gene TGM1 (GeneID: 7051), the KRT1 gene (GeneID: 3848), the KRT10 gene (GeneID: 3858) and the gene KRT14 (GeneID: 3861).
- the KRT1 gene (GeneID: 3848), the KRT10 gene (GeneID: 3858), and the KRT14 gene (GeneID: 3861) encodes the protein keratin, which helps maintain the skin's protective ability.
- the KRT1 gene, the KRT10 gene, and the KRT14 gene encode the proteins keratin 1, keratin 10, and keratin 14.
- Keratin is a fibrous protein that forms the main structure of keratinocytes. Keratin 1, Keratin 10, and Keratin 14 link together to form intermediate filaments that act as strong fiber networks and provide strength and elasticity to the skin. They protect the skin from friction and other physical damages and pack skin cells more closely together, resulting in the reduction of water loss via gaps between skin cells and, consequently, the skin's moisturization.
- red quinoa extract promotes the expression levels of the aforementioned genes and thereby improves skin conditions.
- a concentration of 2 mg/mL or more of red quinoa extract enhances the skin's ability to retain moisture.
- a Degrees Brix of 7.0 or more of red quinoa extract enhances the skin's ability to retain moisture.
- the red quinoa extract is used to prepare a wrinkle soothing and/or skin texture improving composition.
- a concentration of more than 10 wt % of red quinoa extract smoothes out wrinkles and/or improves skin texture.
- a Degrees Brix of 7.0 or more of red quinoa extract enhances the skin's ability to retain moisture.
- the composition is a pharmaceutical composition.
- this pharmaceutical composition comprises an effective amount of red quinoa extract.
- the pharmaceutical composition can be manufactured into a medicament or formula suitable for non-parenteral or oral administration by using ordinary skills in the art.
- medicaments or formulas may include, but are not limited to: tablets, troches, lozenges, pills, capsules, dispersible powders, granules, solutions, suspensions, emulsions, syrups, elixirs, slurries, or other medicaments or formulas having similar functions.
- the pharmaceutical composition can be manufactured into a medicament or formula suitable for non-parenteral or topical administration by using ordinary skills in the art. These medicaments or formulas include but are not limited to: injections, sterile powders, external preparations (external preparation), or other medicaments or formulas having similar functions.
- the pharmaceutical composition may be administered through one of the following non-parenteral routes: subcutaneous injection, intraepidermal injection, intradermal injection, or intralesional injection.
- the pharmaceutical composition may further contain a widely used pharmaceutically acceptable carrier.
- the pharmaceutically acceptable carrier contains one or more of the following reagents: solvents, buffers, emulsifiers, suspending agents, decomposers, disintegrating agents, dispersing agents, binding agents, excipients, stabilizers, chelating agents, diluents, gelling agents, preservatives, wetting agents, lubricants, absorption delaying agents, liposomes or other pharmaceutically acceptable carriers of similar functions.
- solvents solvents, buffers, emulsifiers, suspending agents, decomposers, disintegrating agents, dispersing agents, binding agents, excipients, stabilizers, chelating agents, diluents, gelling agents, preservatives, wetting agents, lubricants, absorption delaying agents, liposomes or other pharmaceutically acceptable carriers of similar functions.
- the pharmaceutically acceptable carrier comprises one or more of the following solvents: water, normal saline, phosphate buffered saline (PBS), an aqueous solution containing alcohol.
- solvents water, normal saline, phosphate buffered saline (PBS), an aqueous solution containing alcohol.
- the composition may be a food composition.
- the food composition may be a food product or a food additive.
- the food additive refers to a matter that is added to manufacture a food product with conventional methods or is added during the production process of a food product. This food product can be formulated with edible materials, and the food product can be consumed by humans or animals.
- the food product may be but are not limited to: drinks (beverages), fermented foods, bakery products, health foods, and dietary supplements.
- Dried red quinoa fruits (husk included) are crushed during the crushing procedure with an Osterizer 10 speed blender.
- the crushed dried quinoa fruits undergo the heating procedure in which water serves as the aqueous solvent.
- the weight ratio of the crushed dried quinoa fruits to the aqueous solvent is 1:10 and the heating procedure is maintained at 85 ⁇ 5° C. for 60 minutes during which the extraction takes place.
- the solution obtained from the heating procedure is cooled to room temperature (25° C.) and is passed through a 400-mesh filter to form a filtrate.
- the filtrate is concentrated under sub-atmospheric pressure at 60° C. until the filtrate reaches a Degrees Brix value of 7.0 ⁇ 5 to give the disclosed red quinoa extract.
- a glycolyzing procedure is added between the filtering procedure and the concentrating procedure. That is, the filtrate is added with a 0.06% starch saccharification enzyme and undergoes a glycolyzing process at 55° C. for 1 hour to obtain a glycolyzed solution.
- a commercially available AMG 300L enzyme is used as the starch saccharification enzyme.
- the aqueous solvent further includes an organic acid, wherein the organic acid is citric acid.
- the amount of citric acid is 0.05 wt % of the overall solvent.
- rutin ChromaDex, Product No. ASB-00018440
- rutin ChromaDex, Product No. ASB-00018440
- a concentration of 200 ⁇ g/mL of rutin methanol solution is used as the standard solution.
- Amounts of 0 ⁇ L, 200 ⁇ L, 400 ⁇ L, 600 ⁇ L, 800 ⁇ L, and 1000 ⁇ L of the standard solution were added to different tubes. Water is then added to the test tubes, such that the total volume of each tube is 1200 ⁇ L.
- the calibration curve of absorbance can be used to convert absorbance value into total flavonoid content. Thereto, an estimation of total flavonoids of the red quinoa extract obtained from EXAMPLE 1 is 1000 ppm.
- Flavonoids are not known to have the uses of improving skin condition or having antioxidative or skin whitening properties. But since it is known that flavonoids may have other uses such as the prevention of cardiovascular disease, the high total flavonoid content in the present disclosure indicates that the red quinoa extract can also have a variety of complex applications. Further, in some embodiments, the total flavonoid content can be used as an endpoint criterion for the concentrating procedure.
- gallic acid equivalents are used to express the relative content of total polyphenols.
- concentrations of 0 ⁇ L/mL, 20 ⁇ L/mL, 40 ⁇ L/mL, 60 ⁇ L/mL, 80 ⁇ L/mL, and 100 ⁇ L/mL of gallic acid (Sigma, product No. G7384) standard solution were made, where 100 ⁇ L of each solution were taken to a new test tube, respectively.
- 500 ⁇ L of Folin-Ciocalteu's phenol reagent is added, mixed well, and left to stand for 3 minutes.
- test tube solution is mixed well and allowed to react for 30 minutes. After oscillation (Vortex) and ensuring that no air bubbles are present, take 200 ⁇ L of the solution and record its absorbance value at a wavelength of 750 nm. Plot the absorbance values of the six different concentrations of gallic acid solution to give a calibration curve.
- the calibration curve of absorbance can be used to convert absorbance value into total polyphenol content. Thereto, an estimation of total polyphenols of the red quinoa extract obtained from EXAMPLE 1 is 400 ppm.
- Polyphenols are not known to have the uses of improving skin condition, or having antioxidative or skin whitening properties. But since it is known that polyphenols may have other uses such as the prevention of cardiovascular disease, the high total polyphenol content in the present disclosure indicates that the red quinoa extract can also have a variety of complex applications. Further, in some embodiments, the total polyphenol content can be used as an endpoint criterion for the concentrating procedure.
- Tyrosinase has a key role in the synthesis of melanin. Tyrosinase catalyzes the conversion of tyrosine to L-Dopa, which is further produced into Dopaquinone and then to melanin. Thus, by detecting the activity of tyrosinase, melanocytes' ability to produce melanin can be inferred. When the activity of tyrosinase is low, the melanin production capacity of melanocytes is relatively reduced.
- This experiment is divided into three groups: the control group, experimental group A, and experimental group B.
- the control group is added with 2 mL of fresh medium and incubated for 48 hours;
- experimental group A is added with 2 mL of 1 mg/mL red quinoa extract and incubated for 48 hours;
- experimental group B is added with 2 mL of 0.5 mg/mL red quinoa extract, and incubated for 48 hours.
- the red quinoa extract samples in experimental groups A and B were obtained by mixing 2 mL of medium with 14.3 ⁇ L and 28.6 ⁇ L of the red quinoa extract prepared from EXAMPLE 1.
- the medium is removed and washed with 1 ⁇ PBS (Gibco) twice. Trypsin-EDTA was added to the wells and to react for 3 minutes. The cells were then retrieved from the suspension and taken into 15 mL centrifuge tubes, where they were centrifuged for 5 minutes at 400 ⁇ g to pellet the cells.
- the precipitated cells were washed twice with 1 ⁇ PBS, suspended with 200 ⁇ L cell lysate, vortexed, and centrifuged for 20 min at 12,000 ⁇ g.
- Bio-rad dye is mixed with deionized water (volume ratio 1:4) and distributed into 7 microcentrifuge tubes, each having 500 ⁇ L of the solution. Then, the microcentrifuge tubes were added with 10 ⁇ L, 8 ⁇ L, 6 ⁇ L, 4 ⁇ L, 2 ⁇ L, 1 ⁇ L, and 0 ⁇ L of 2 mg/mL BSA, respectively to prepare the standard protein concentration sample. Next, 2 ⁇ L of supernatant is added to each microcentrifuge tube for testing. The microcentrifuge tubes were then added to the wells of a 96 well plate where each well is added with 200 ⁇ L of protein assay reagent. Then, the absorbance value was measured at 595 nm using the ELISA reader (BioTek).
- Tyrosinase inhibition is calculated with the following formula:
- Tyrosinase Inhibition (%) (OD sample/OD control) ⁇ 100%.
- the tyrosinase inhibition is improved in the group containing the red quinoa extract and increases with the red quinoa extract concentration.
- experimental group B 0.5 mg/mL of red quinoa extract
- experimental group A 1 mg/mL of red quinoa extract
- the red quinoa extract disclosed herein reduces tyrosinase activity, which, in turn, reduces the formation of melanin. This shows that the red quinoa extract disclosed here can be used to reduce skin spots, improve skin condition, whiten the skin.
- This example demonstrates the melanin content reducing capability of the red quinoa extract disclosed herein by quantifying the difference in melanin content after treating B16F10 melanoma cells with the red quinoa extract disclosed herein with ELISA reader (enzyme-linked immunosorbent assay reader).
- control group is added with 2 mL of fresh medium and incubated for 48 hours.
- the control group is moved to a dark room and allowed to stand at room temperature for 3 hours.
- the melanin content of the experiment group is 29.7% lower than the control group, indicating that the red quinoa extract disclosed herein has can effectively reduce the production of melanin in melanocytes.
- This example uses an RNA extraction kit, reverse transcriptase, a KAPA SYBR® FAST qPCR reagent kit, and quantitative PCR to determine the expression of antioxidation-related genes in human skin fibroblasts (CCD-966sk) after being treated by the red quinoa extract disclosed herein.
- the cell culture experiment process is as follows:
- control group is added with 2 mL of fresh medium and incubated for 6 hours
- the polymerase chain reaction experiment process is as follows:
- FIG. 5 shows the relative expression levels of the antioxidation-related genes of the experiment and control group.
- the relative expression level of the SOD2 gene in the experimental group is 2725%.
- the expression level of the antioxidation-related SOD2 gene in the experimental group increased 2625%, reaching statistical significance.
- the red quinoa extract disclosed herein has free radical scavenging properties and can function as an antioxidant.
- This example uses an RNA extraction kit, reverse transcriptase, a KAPA SYBR® FAST qPCR reagent kit, and quantitative PCR to determine the expression of moisture-related genes in human epidermal keratinocytes (HPEK-50) after treatment of the red quinoa extract disclosed herein.
- HPEK-50 human epidermal keratinocytes
- the cell culture experiment process is as follows:
- control group is added with 2 mL of fresh medium and incubated for 6 hours
- the TGM1 gene's corresponding primer pair is TGM1-F and TGM1-R
- the KRT1 gene's corresponding primer pair is KRT1-F and KRT1-R
- the KRT10 gene's corresponding primer pair is KRT10-F and KRT10-R
- the TBP gene's corresponding primer pair is TBP-F and TBP-R.
- FIG. 6 shows the relative expression levels of the moisture-related genes of the experiment and control group.
- the relative expression levels of the TGM1 gene, the KRT1 gene, and the KRT10 gene are 234%, 432% and 435%, respectively.
- the expression level of the TGM1 gene, the KRT1 gene, and the KRT10 gene in the experimental group increased 134%, 332%, and 335%, respectively, all reaching statistical significance.
- the red quinoa extract disclosed herein can prevent skin water loss, moisturize the skin and improve skin function.
- This example demonstrates the antioxidation and skin condition, improving properties of the red quinoa extract disclosed herein by administering drinks containing the red quinoa extract disclosed in the present invention to human subjects.
- red quinoa extract 50 g/bottle which comprises: red quinoa extracted 10 wt %, apple juice concentrate 6 wt %, fructose 6 wt %, 0.4 wt % citrus pectin, citric acid 0.2 wt %, apple liquid spices 0.24 wt %, water 77.16 wt %.
- the intake of red quinoa extract can be up to 10 g/day.
- the red quinoa extract herein is produced with the method detailed in EXAMPLE 1.
- the concentrated apple juice 6 wt %, fructose 6 wt %, citrus pectin 0.4 wt %, citric acid 0.2 wt %, apple liquid spices 0.24 wt % are meant to flavor and to enhance the shelf life of the beverage.
- Number of subjects 30 subjects, 30-55 years of age.
- the skin hydration probe Corneometer® CM825 (C+K M ⁇ Lti Probe Adapter System, Germany) is used to detect facial skin hydration in both groups.
- the values of the detection probe are based on capacitive measurement. Since the capacitance value of the skin changes with the skin's hydration, the detection probe can analyze skin hydration by measuring skin capacitance values.
- the 3D analytical lens of Antera 3D is used to detect facial skin color in both groups.
- the instrument first emits lights using its LED (light-emitting diodes) at different wavelengths and angles and then collects the reflected lights that bounce off of the skin to analyze the skin color.
- Antera uses colorimeter to analyze color, which depends on the parameters L*a*b* in which L* refers to brightness: the a* axis represents the green-red component, with green in the negative direction and red in the positive direction; the b* axis represents the blue-yellow component, with blue in the negative direction and yellow in the positive direction.
- color 1 (L* 1 , a* 1 , b* 1 ) and color 2 (L* 2 , a* 2 , b* 2 ) can be calculated by the following formula:
- ⁇ E* ab ⁇ square root over (( L* 2 ⁇ L* 1 ) 2 +( a* 2 ⁇ a* 1 ) 2 +( b* 2 ⁇ b* 1 ) 2 ) ⁇
- Skin texture is measured using the VISIA Digital Skin Detector (Canfield, US).
- the instrument uses visible light to capture high-resolution images of the skin and uses its built-in software to analyze skin roughness. The higher the measured value is, the rougher the skin is.
- the Soft Plus Skin Detector (Callegari 1930) is used to measure the end of the subjects' eyes to evaluate crow's feet.
- the instrument detects the area of shades against standard light to quantify the depth of crow's feet.
- the collected blood samples were transferred into a centrifuge tube and centrifuged at 700-1000 ⁇ g, 4° C. for 10 minutes. After centrifugation, the upper plasma layer is removed, and 2 mL of the blood cell layer (i.e., buffy coat) is placed in another centrifuge tube where 2 mL of PBS is added and mixed to provide a diluted buffy coat.
- the blood cell layer i.e., buffy coat
- the standard formaldehyde group takes up seven wells, wherein each well contains 100 ⁇ L of buffer solution, 30 L of methanol, and 20 ⁇ L of the standard solution (tube A to G);
- the positive control group takes up two wells, wherein each well contains 100 ⁇ L of buffer solution, 30 L of methanol, and 20 ⁇ L of the diluted antioxidant enzymes; while the experimental group wells contain 100 ⁇ L of buffer solution, 30 ⁇ L of methanol and 20 ⁇ L of the experimental samples (i.e., the processed blood samples).
- Catalase Content is calculated as follows:
- Formaldehyde concentration ( ⁇ M) ((absorbance value of experimental group ⁇ y-intercept of the drawing made)/slope of the drawing made)*(0.17 mL/0.02 mL)
- the catalase content is set at 100% at week 0 for both the placebo and control group to better present the relative catalase content of the groups.
- FIG. 7 shows the average skin hydration percentage at week 0, week 4, and week 8 of the placebo group and the experiment group.
- week 4 93% of the subjects had an increase in skin hydration
- week 8 100% of the subjects had an increase in skin hydration.
- the test subjects' average skin hydration percentage before beverage consumption is 100%
- the average skin hydration percentage after 4 weeks of consumption is 109.3%
- the average skin hydration percentage after 8 weeks of consumption is 113.9%.
- the subjects in the experimental group had an average increase of 9.3% and 13.9% in skin hydration, respectively, both reaching statistical significance.
- the average skin hydration percentages of the experiment group in week 4 and week 8 were also higher than those of the placebo group in week 4 and week 8 by 5.1% and 6.6%, respectively.
- the present disclosed red quinoa extract can be used to moisturize the skin and maintain skin moisture retention.
- FIG. 8 shows the average skin color percentage at week 0, week 4, and week 8 of the placebo group and the experiment group.
- week 4 93% of the subjects had an increase in skin color
- week 8 100% of the subjects had an increase in skin color.
- the test subjects' average skin color percentages before beverage consumption are 100%
- the average skin color percentage after 4 weeks of consumption is 103.0%
- the average skin color percentage after 8 weeks of consumption is 103.8%.
- the subjects in the experimental group had an average increase of 3.0% and 3.8% in skin color, respectively, both reaching statistical significance.
- the average skin color percentages of the experiment group in week 4 and week 8 were also higher than those of the placebo group in week 4 and week 8 by 3.6% and 4.1%, respectively.
- the present disclosed red quinoa extract can be used to brighten and whiten skin color.
- FIG. 9 shows the average skin texture percentage at week 0, week 4, and week 8 of the placebo group and the experiment group.
- week 4 73% of the subjects had an increase in skin texture
- week 8, 83% of the subjects had an increase in skin texture.
- the test subjects' average skin texture percentage before beverage consumption is 100%
- the average skin texture percentage after 4 weeks of consumption is 91.1%
- the average skin texture percentage after 8 weeks of consumption is 90.2%.
- the subjects in the experimental group had an average decrease of 8.9% and 9.8% in skin texture, respectively.
- the average skin texture percentages of the experiment group in week 4 and week 8 were also lower than those of the placebo group in week 4 and week 8 by 10.6% and 18.1%, respectively.
- the present disclosed red quinoa extract can be used to improve skin texture and reduce the roughness of the skin
- FIG. 10 shows the average crow's feet percentage at week 0, week 4, and week 8 of the placebo group and the experiment group.
- 100% of the subjects had a decrease in crow's feet percentage.
- the average crow's feet percentage after 4 weeks of consumption is 81.5%
- the average crow's feet percentage after 8 weeks of consumption is 78.5%.
- the subjects in the experimental group had an average decrease of 18.5% and 21.5% in crow's feet, respectively, both reaching statistical significance.
- the average crow's feet percentages of the experiment group in week 4 and week 8 were also lower than those of the placebo group in week 4 and week 8 by 9.9% and 8.9%, respectively.
- the present disclosed red quinoa extract can be used to soothe wrinkles
- FIG. 11 shows the average in vivo antioxidant enzyme (catalase) percentage at week 0, week 4, and week 8 of the placebo group and the experiment group.
- Catalase antioxidant enzyme
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
- This non-provisional application claims the benefit of U.S. provisional application Ser. No. 62/934,014, filed on Nov. 12, 2019, the entire contents of which are hereby incorporated by reference.
- The contents of the electronic sequence listing (2138-US-UT001_SEQLIST_ST25.txt; Size: 2.3 KB; and Date of Creation: Nov. 12, 2020) is herein incorporated by reference in its entirety.
- The present invention relates to a use of Chenopodium formosanum (Djulis) extract, particularly to the use of Chenopodium formosanum (Djulis) extract for the use of antioxidation and improving skin appearance, including skin moisturizing, skin whitening, and skin wrinkle smoothing.
- Chenopodium formosanum (Djulis), also known as Taiwan quinoa, red quinoa, purple quinoa, and rainbow rice, is an annual herb and an endemic species found in Taiwan. It is a close relative of quinoa and belongs to the Chenopodiaceae family and the genus Chenopodium. Distributed in the middle and low altitude mountain areas of central and southern Taiwan, it has more than a hundred years in aboriginal farming history. At present, the aboriginal tribe of Paiwan in Eastern Taiwan has the most abundant seed resources. Red quinoa is edible, and its seedlings, tender stems, and flower spikes can be added to cooking or boiling soup. Red quinoa seeds can also be ground into a powder to serve as raw materials for glutinous rice balls.
- The protein content of red quinoa is twice that of rice. The fruit of red quinoa is often dried, hulled, and mixed with other grains to serve as general edible rice. In food processing, different processing methods (steaming, microwave, roasting, frying, and puffing) can be used to make rice balls, biscuits, potato balls, puffs, mochi, muffins, and fragrant rice products. Red quinoa can serve as a garnish for plating and provide rich nutritional value, and is gradually being loved by more and more consumers.
- The present invention discloses a red quinoa extract for improving skin conditions. The composition can be used as an antioxidant or for skin whitening and skin moisturizing purposes.
- In some embodiments, the red quinoa extract scavenges free radicals in cells, wherein the red quinoa extract is extracted with an aqueous solvent. In some embodiments, the cell is a skin cell.
- In some embodiments, the red quinoa extract achieves the antioxidant effect by enhancing the expression level of antioxidant-related genes.
- In some embodiments, the antioxidant-related genes include at least one of the SOD1 gene, the SOD2 gene, or the CAT gene.
- In some embodiments, the red quinoa extract achieves the antioxidant effect by increasing the abundance of antioxidant enzymes in a body.
- In some embodiments, the Degrees Brix value of the red quinoa extract is 7.0±5.
- In some embodiments, the red quinoa extract is used to prepare a composition for improving skin condition, wherein the red quinoa extract is extracted with an aqueous solvent.
- In some embodiments, the red quinoa extract is used to prepare a skin whitening composition, wherein the red quinoa extract is extracted with an aqueous solvent.
- In some embodiments, the red quinoa extract achieves the skin whitening effect by inhibiting tyrosinase activity and/or reducing the amount of melanin production.
- In some embodiments, the red quinoa extract is used to prepare a skin moisturizing composition, and the red quinoa extract is extracted with an aqueous solvent.
- In some embodiments, the red quinoa extract achieves the skin's moisturizing effect by enhancing the expression of skin moisturizing-related genes.
- In some embodiments, skin moisturizing-related genes include at least one of the TGM1 gene, the KRT1 gene, the KRT10 gene, and the KRT14 gene.
- In some embodiments, the aqueous solvent is water or a solvent containing organic acids. In some embodiments, the concentration of the organic acid is 0.05%-1.00%.
- In some embodiments, the red quinoa extract is formed by first extracting red quinoa with an aqueous solvent and then undergoing glycolysis using a saccharification enzyme.
- In summary, the red quinoa extract of any embodiment can be used to prepare an antioxidant composition. The red quinoa extract of any embodiment can be used to prepare a composition that improves the expression of antioxidant-related genes (such as the SOD1 gene, the SOD2 gene, or the CAT gene) in cells. The red quinoa extract of any embodiment can be used to prepare a composition for enhancing antioxidant enzymes in the body. The red quinoa extract of any embodiment can be used to prepare a skin moisturizing composition. The red quinoa extract of any embodiment can be used to prepare a composition that improves the expression of moisturizing-related genes (such as the TGM1 gene, the KRT1 gene, the KRT10 gene, the KRT14 gene) in cells. The red quinoa extract of any embodiment can be used to prepare a skin whitening composition. The red quinoa extract of any embodiment can be used to prepare a composition that inhibits tyrosine expression. The red quinoa extract of any embodiment can be used to prepare a composition that inhibits melanin formation.
-
FIG. 1 shows an embodiment of a method for preparing red quinoa extract. -
FIG. 2 shows another embodiment of a method for preparing red quinoa extract. -
FIG. 3 shows the tyrosine inhibition ratios of the experimental and control groups in EXAMPLE 4. -
FIG. 4 shows the melanin production ratios of the experimental and control groups in EXAMPLE 5. -
FIG. 5 shows the gene expression ratios of the antioxidant-related genes in the experimental and control groups in EXAMPLE 6. -
FIG. 6 shows the gene expression ratios of the moisturizing-related genes in the experimental and control groups in EXAMPLE 7. -
FIG. 7 shows skin moisture retention ratios of the experimental and placebo groups in EXAMPLE 8 after intake of health drinks with and without the red quinoa extract, respectively, for 4 weeks and 8 weeks. -
FIG. 8 shows skin whiteness ratios of the experimental and placebo groups in EXAMPLE 8 after intake of health drinks with and without the red quinoa extract, respectively, for 4 weeks and 8 weeks. -
FIG. 9 shows skin texture ratios of the experimental and placebo groups in EXAMPLE 8 after intake of health drinks with and without the red quinoa extract, respectively, for 4 weeks and 8 weeks. -
FIG. 10 shows crow's feet proportions of the experimental and placebo groups in EXAMPLE 8 after intake of health drinks with and without the red quinoa extract, respectively, for 4 weeks and 8 weeks. -
FIG. 11 shows the amount of antioxidant enzyme present in the bodies of the experimental and placebo groups in EXAMPLE 8 after intake of health drinks with and without the red quinoa extract, respectively, for 4 weeks and 8 weeks. - Some embodiments of the present invention are described below. The present invention can be practiced in many different embodiments. It should be noted that the scope of the present invention is not limited to the embodiments specified in the present specification.
- Microsoft's Excel software is used for statistical analysis in the present invention. The data are expressed as mean±standard deviation (SD), and the differences between groups are analyzed by student's t-test. In the diagram, “*” represents a p-value smaller than 0.05, “**” represents a p-value smaller than 0.01, and “***” represents a p-value smaller than 0.001. The more “*”'s are present, the more significant is the statistical difference.
- The numerical values used in this article are approximate, and all experimental data all include a margin of error of 10%. In some embodiments, the margin of error is 5%.
- In this article, “wt %” refers to percentage by weight, and “vol %” refers to percentage by volume.
- As used herein, the term “extract” refers to a product prepared through extraction. The extract can be presented in the form of a liquid solution or a form of a concentrate or essence containing no or little solvent.
- As used herein, “raw red quinoa material” generally refers to the plant's seeds, wherein the seeds may include fresh red quinoa, dried red quinoa, or red quinoa processed by other physical methods. The physical methods may include chopping, dicing, or crushing. Any physical process that renders the seed different from its original physical property is considered a physical method.
- Referring to
FIG. 1 , in some embodiments, the red quinoa extract is extracted from raw red quinoa material with an aqueous solvent. In some embodiments, the red quinoa (Chenopodium formosanum (Djulis)) extract is obtained by sequentially performing the crushing procedure S01, heating procedure S02, filtering procedure S04, and concentrating procedure S06. - In some embodiments, the raw red quinoa material is hulled red quinoa seeds. In some embodiments, the red quinoa raw material may be fresh or dried red quinoa seeds.
- In some embodiments, the crushing procedure S01 refers to grinding or crushing the raw red quinoa material until it becomes powdered raw red quinoa material. A juicer, a blender, or a homogenizer can be used to perform the crushing procedure 01.
- In some embodiments, the heating procedure S02 refers to mixing powdered raw red quinoa material with an aqueous solvent and heating it for a fixed period. In some embodiments, heating refers to increasing the raw red quinoa material's temperature and its aqueous solvent to 50° C. to 100° C. In some embodiments, a fixed period of time refers to 0.5 hours to 3 hours. An example of an embodiment is mixing the powdered raw red quinoa material with an aqueous solvent and increasing the temperature of the solution to 85° C. and maintaining such temperature for 1 hour.
- In some embodiments, during the heating procedure S02, the weight ratio of the aqueous solvent to the raw red quinoa material ranges from is 5:1-20:1. For example, the weight ratio of the aqueous solvent to the raw red quinoa material can be 10:1.
- In some embodiments, the aqueous solvent is water or a water solvent containing organic acids. In some embodiments, the concentration of the organic acid is 0.05% to 1.00%. In some embodiments, the organic acid and its concentration are at an edible state. In some embodiments, the organic acid may be citric acid, malic acid, tartaric acid, lactic acid, gluconic acid, acetic acid, but is not limited thereto.
- An example of an embodiment is mixing 90 kg of raw red quinoa material with 900 kg of water and 0.63 kg of citric acid, heating them to 100° C. and maintaining them at 100° C. for 0.5 hours. Another example is mixing 90 kg of raw red quinoa material with 900 kg of water and 0.7 kg of citric acid and then heating them to 85° C. and maintaining 85° C. for 1 hour.
- In some embodiments, the filtering procedure S04 refers to passing the heated (or cooled) raw red quinoa material and the aqueous solvent through a filter to filter out the solids or large particles in the solvent to form a filtrate. In some embodiments, the filter is a 400-mesh filter.
- Referring to
FIG. 2 , in some embodiments, between the heating procedure 02 and the filtering procedure S04 is a cooling process S03. The cooling process S03 refers to cooling the processed raw red quinoa materials and its aqueous solvent to room temperature. - In some embodiments, the concentrating procedure S06 refers to obtaining a first filtrate by concentrating the filtrate obtained from the filtering procedure S04 under reduced pressure (brand/model: BUCHI-Rotavapor R-100). In some embodiments, the first extract is the red quinoa extract. In some embodiments, the concentrating procedure S06 provides an environment of 40° C.˜70° C. with reduced atmospheric pressure for concentrating. An example of an embodiment of the red quinoa extract is obtained by first crushing raw red quinoa material into powder through the crushing procedure S01, then undergoing the heating procedure S02, the filtering procedure, and the concentrating procedures S06.
- In some embodiments, between the filtering procedure S04 and the concentrating procedure S06 is a glycolyzing procedure S05. During the glycolyzing procedure S05, a glycolysis enzyme is added to, stirred with, and mixed with the filtrate obtained from the filtering procedure S04 and then allowed to stand for at least 1 hour to give a glycolyzed solution. Glycolysis enzymes further enhance the effect of bioactive ingredients in the red quinoa extract. In some embodiments, the glycolysis enzymes may be α-amylase, [beta]-amylase, glucoamylase, isoamylase, or a mixture of at least one. In some embodiments, the glycolysis enzymes may be glucose amylase (glucan 1,4-alpha-glucosidase). In some embodiments, the filtrate obtained from the filtering procedure S04 is added with a 0.06% amount of starch saccharification enzymes. In some embodiments, the S05 glycolyzing procedure includes adding a 0.06% amount of a starch saccharification enzyme to the filtrate obtained from the filtering procedure 04 and then heated to and maintained at 55° C. maintained for more than 1 hour to obtain a glycolyzed solution.
- In other embodiments, the S06 concentrating procedure concentrates the glycolyzed solution obtained from the glycolyzed solution S05 with reduced atmospheric pressure.
- In some embodiments, after the concentrating procedure S06 is a second filtering procedure S07. The second filtering procedure S07 refers to passing the glycolyzed solution obtained by the glycolyzing procedure S06 through a 400-mesh filter to obtain the red quinoa extract. An example of an embodiment of red quinoa extract is obtained by sequentially going through the crushing procedure S01, the heating procedure S02, the filtering procedure S04, the glycolyzing procedure S05, the concentrating procedure S07, and the second filtering procedure S07.
- In some embodiments, the red quinoa extract is used to prepare an antioxidant composition, wherein the red quinoa extract achieves the antioxidating effect by promoting the expression of genes related to antioxidation, and wherein the red quinoa extract is extracted with an aqueous solvent. In some embodiments, the red quinoa extract achieves the antioxidating effect by increasing antioxidant enzymes in a body.
- In some embodiments, antioxidation refers to the slowing down of or the prevention of oxidation. Oxidation refers to a chemical reaction in which one or more elections are transferred from one matter to another. This chemical reaction may generate a radical species and consequently start a chain reaction. When a chain reaction occurs in a cell, the cell will be susceptible to damage or apoptosis. In some embodiments, the red quinoa extract removes free radicals, terminate the chain reaction, or inhibits other oxidation reactions. In some embodiments, the radical species in a cell are generated due to light, chemicals, or the natural process of aging.
- In some embodiments, the antioxidant-related genes include at least one of the SOD1 gene (GeneID: 6647), the SOD2 gene (GeneID: 6648), or the CAT gene (GeneID: 847).
- As described above, superoxide anions, hydrogen peroxides, and other free radicals can damage skin cells. Proteins transcribed by the SOD1 gene and the SOD2 gene (superoxide dismutase) break down superoxide into hydrogen peroxide. The protein transcribed by the CAT gene breaks down hydrogen peroxide into water and oxygen. The genes transcribe proteins that are important for the removal of free radicals. Thus, the more increased is the expression of these genes in a cell, the better the cell's antioxidant capacity is.
- In other words, by promoting the expression of the aforementioned antioxidation-related genes, the red quinoa extract effectively enhances cellular antioxidation capacity, improves cellular resistance to free radicals, thus protecting skin cells and improving skin condition.
- In some embodiments, a concentration of 2 mg/mL of red quinoa extract promotes expression levels of antioxidation-related genes, removes free radicals, and increases cellular antioxidation capacity.
- In some embodiments, a red quinoa extract having a Degrees Brix of 7.0 or more improves the expression levels of antioxidation-related genes, removes free radicals, and increases cellular antioxidation capacity.
- In some embodiments, a red quinoa extract is used to prepare a skin whitening or brightening composition, wherein the red quinoa extract is achieved the skin whitening or brightening by inhibiting melanin production or inhibiting tyrosine production, wherein the red quinoa extract obtained from an aqueous solvent.
- The production of melanin darkens the skin, and during the process of melanin production, tyrosinase plays a crucial role. Tyrosinase is a rate determine enzyme that regulates melanogenesis. Specifically, tyrosinase is involved in two reactions during melanin synthesis: (1) the conversion of a phenolic hydroxyl group into a single diphenol, (2) the oxidation of diphenols to quinones. The enzyme tyrosinase is present in skin melanocytes and is encoded in the TYR gene.
- In some embodiments, the red quinoa extract suppresses tyrosinase formation to inhibit, prevent, or slow down melanin production in the skin, which in turn whitens or brightens the skin.
- In some embodiments, a concentration of 1 mg/mL of red quinoa extract is used to whiten and brighten skin.
- In some embodiments, red quinoa extract with a Degrees Brix of 7.0 or more is used to whiten and brighten skin.
- In some embodiments, the red quinoa extract is used to prepare a skin moisturizing composition, wherein the red quinoa extract is extracted with an aqueous solvent, and wherein the red quinoa extract s extracted quinoa through ascension the amount of moisture associated gene expression to achieve the effect of moisturizing the skin.
- During daily activities, the skin is prone to water loss due to the weather, the external environment, or even aging. This water loss is accelerated if the gaps between skin cells are increased. This acceleration of water loss results in the reduction of skin brightness and moisture retention capacity.
- In some embodiments, moisture-related genes include the gene TGM1 (GeneID: 7051), the KRT1 gene (GeneID: 3848), the KRT10 gene (GeneID: 3858) and the gene KRT14 (GeneID: 3861).
- The KRT1 gene (GeneID: 3848), the KRT10 gene (GeneID: 3858), and the KRT14 gene (GeneID: 3861) encodes the protein keratin, which helps maintain the skin's protective ability.
- Specifically, the KRT1 gene, the KRT10 gene, and the KRT14 gene encode the proteins keratin 1,
keratin 10, and keratin 14. Keratin is a fibrous protein that forms the main structure of keratinocytes. Keratin 1,Keratin 10, and Keratin 14 link together to form intermediate filaments that act as strong fiber networks and provide strength and elasticity to the skin. They protect the skin from friction and other physical damages and pack skin cells more closely together, resulting in the reduction of water loss via gaps between skin cells and, consequently, the skin's moisturization. - In other words, red quinoa extract promotes the expression levels of the aforementioned genes and thereby improves skin conditions.
- In some embodiments, a concentration of 2 mg/mL or more of red quinoa extract enhances the skin's ability to retain moisture.
- In some embodiments, a Degrees Brix of 7.0 or more of red quinoa extract enhances the skin's ability to retain moisture.
- In some embodiments, the red quinoa extract is used to prepare a wrinkle soothing and/or skin texture improving composition.
- In some embodiments, a concentration of more than 10 wt % of red quinoa extract smoothes out wrinkles and/or improves skin texture.
- In some embodiments, a Degrees Brix of 7.0 or more of red quinoa extract enhances the skin's ability to retain moisture.
- In some embodiments, the composition is a pharmaceutical composition. In other words, this pharmaceutical composition comprises an effective amount of red quinoa extract.
- In some embodiments, the pharmaceutical composition can be manufactured into a medicament or formula suitable for non-parenteral or oral administration by using ordinary skills in the art. These medicaments or formulas may include, but are not limited to: tablets, troches, lozenges, pills, capsules, dispersible powders, granules, solutions, suspensions, emulsions, syrups, elixirs, slurries, or other medicaments or formulas having similar functions.
- In some embodiments, the pharmaceutical composition can be manufactured into a medicament or formula suitable for non-parenteral or topical administration by using ordinary skills in the art. These medicaments or formulas include but are not limited to: injections, sterile powders, external preparations (external preparation), or other medicaments or formulas having similar functions. In some embodiments, the pharmaceutical composition may be administered through one of the following non-parenteral routes: subcutaneous injection, intraepidermal injection, intradermal injection, or intralesional injection.
- In some embodiments, the pharmaceutical composition may further contain a widely used pharmaceutically acceptable carrier. In some embodiments, the pharmaceutically acceptable carrier contains one or more of the following reagents: solvents, buffers, emulsifiers, suspending agents, decomposers, disintegrating agents, dispersing agents, binding agents, excipients, stabilizers, chelating agents, diluents, gelling agents, preservatives, wetting agents, lubricants, absorption delaying agents, liposomes or other pharmaceutically acceptable carriers of similar functions. The selection and quantification of these agents are routine practice and techniques for people having ordinary skill in the art.
- In some embodiments, the pharmaceutically acceptable carrier comprises one or more of the following solvents: water, normal saline, phosphate buffered saline (PBS), an aqueous solution containing alcohol.
- In some embodiments, the composition may be a food composition. In some embodiments, the food composition may be a food product or a food additive. The food additive refers to a matter that is added to manufacture a food product with conventional methods or is added during the production process of a food product. This food product can be formulated with edible materials, and the food product can be consumed by humans or animals.
- In some embodiments, the food product may be but are not limited to: drinks (beverages), fermented foods, bakery products, health foods, and dietary supplements.
- Dried red quinoa fruits (husk included) are crushed during the crushing procedure with an
Osterizer 10 speed blender. Next, the crushed dried quinoa fruits undergo the heating procedure in which water serves as the aqueous solvent. The weight ratio of the crushed dried quinoa fruits to the aqueous solvent is 1:10 and the heating procedure is maintained at 85±5° C. for 60 minutes during which the extraction takes place. Then, the solution obtained from the heating procedure is cooled to room temperature (25° C.) and is passed through a 400-mesh filter to form a filtrate. Finally, the filtrate is concentrated under sub-atmospheric pressure at 60° C. until the filtrate reaches a Degrees Brix value of 7.0±5 to give the disclosed red quinoa extract. - In some embodiments, a glycolyzing procedure is added between the filtering procedure and the concentrating procedure. That is, the filtrate is added with a 0.06% starch saccharification enzyme and undergoes a glycolyzing process at 55° C. for 1 hour to obtain a glycolyzed solution. Hereto, a commercially available AMG 300L enzyme is used as the starch saccharification enzyme.
- In some embodiments, the aqueous solvent further includes an organic acid, wherein the organic acid is citric acid. The amount of citric acid is 0.05 wt % of the overall solvent.
- Using water, dilute the red quinoa extract obtained from EXAMPLE 1 ten-fold in terms of volume and take 200 μL of the diluted solution to a test tube. Add 5 wt % of sodium nitrite (Sigma, product No. 31443) to the test tube and allow the reaction to stand for 6 minutes.
- Next, add 10 wt % of aluminum nitrate (Alfa Aesar, product No. 12360) to the test tube solution, and let the reaction stand for 6 minutes. Then, after adding 2 mL of 4 wt % aqueous sodium hydroxide (Macron, product No. 7708-10) to the solution, add 1.4 mL of water to the test tube and mix evenly to obtain the reaction solution. Take 200 μL of reaction solution into a 96-well reaction plate and detect the absorbance value at a wavelength of 500 nm using a spectrophotometer (Jasco, Model V-730).
- Then, prepare standard solutions for the calibration curve: Hereto, rutin (ChromaDex, Product No. ASB-00018440) equivalents are used to express the relative content of total flavonoids. First, a concentration of 200 μg/mL of rutin methanol solution is used as the standard solution. Amounts of 0 μL, 200 μL, 400 μL, 600 μL, 800 μL, and 1000 μL of the standard solution were added to different tubes. Water is then added to the test tubes, such that the total volume of each tube is 1200 μL. Next, for the solution in each tube, 200 μL is taken to mix with 200 μL of 5 wt % aqueous sodium nitrite solution in a new test tube where the reaction is allowed to stand or 6 minutes. Followed by the addition of 200 μL 10 wt % aqueous aluminum nitrate solution, the reaction is allowed to stand for 6 minutes. Then add 2 mL of 4 wt % sodium hydroxide aqueous solution for homogenization. Next 1.4 mL of water is added to the tube and mixed to obtain a reaction solution. Finally, take 200 μL of the reaction solution into a 96-well reaction plate and detect the absorbance value at a wavelength of 500 nm using a spectrophotometer (Jasco, Model V-730). Plot the absorbance values of the six different concentrations of rutin to give a calibration curve.
- The calibration curve of absorbance can be used to convert absorbance value into total flavonoid content. Thereto, an estimation of total flavonoids of the red quinoa extract obtained from EXAMPLE 1 is 1000 ppm.
- Flavonoids are not known to have the uses of improving skin condition or having antioxidative or skin whitening properties. But since it is known that flavonoids may have other uses such as the prevention of cardiovascular disease, the high total flavonoid content in the present disclosure indicates that the red quinoa extract can also have a variety of complex applications. Further, in some embodiments, the total flavonoid content can be used as an endpoint criterion for the concentrating procedure.
- Using water, dilute the red quinoa extract obtained from EXAMPLE 1 ten-fold in terms of volume and take 100 μL of the diluted solution to a test tube. Then, add 500 μL of Folin-Ciocalteu's phenol reagent (Merck, Product No. 1.09001.0100), mix well, and leave to stand for 3 minutes. Then add 400 μL of 7.5 wt % sodium carbonate (Sigma, Product No. 31432) to the test tube, mix well, and allow it to react for 30 minutes. After oscillation (Vortex) and ensuring that no air bubbles are present, take 200 μL of the solution and record its absorbance value at a wavelength of 750 nm.
- Next, prepare the standard solutions to produce the calibration curve. Hereto, gallic acid equivalents are used to express the relative content of total polyphenols. Thereto, concentrations of 0 μL/mL, 20 μL/mL, 40 μL/mL, 60 μL/mL, 80 μL/mL, and 100 μL/mL of gallic acid (Sigma, product No. G7384) standard solution were made, where 100 μL of each solution were taken to a new test tube, respectively. For each test tube, 500 μL of Folin-Ciocalteu's phenol reagent is added, mixed well, and left to stand for 3 minutes. Followed by the addition of 400 μL of 7.5 wt % aqueous sodium carbonate solution, the test tube solution is mixed well and allowed to react for 30 minutes. After oscillation (Vortex) and ensuring that no air bubbles are present, take 200 μL of the solution and record its absorbance value at a wavelength of 750 nm. Plot the absorbance values of the six different concentrations of gallic acid solution to give a calibration curve.
- The calibration curve of absorbance can be used to convert absorbance value into total polyphenol content. Thereto, an estimation of total polyphenols of the red quinoa extract obtained from EXAMPLE 1 is 400 ppm.
- Polyphenols are not known to have the uses of improving skin condition, or having antioxidative or skin whitening properties. But since it is known that polyphenols may have other uses such as the prevention of cardiovascular disease, the high total polyphenol content in the present disclosure indicates that the red quinoa extract can also have a variety of complex applications. Further, in some embodiments, the total polyphenol content can be used as an endpoint criterion for the concentrating procedure.
- Tyrosinase has a key role in the synthesis of melanin. Tyrosinase catalyzes the conversion of tyrosine to L-Dopa, which is further produced into Dopaquinone and then to melanin. Thus, by detecting the activity of tyrosinase, melanocytes' ability to produce melanin can be inferred. When the activity of tyrosinase is low, the melanin production capacity of melanocytes is relatively reduced.
- Materials and Equipment
-
- 1. Cell line: B16F10 mouse melanoma cells, purchased from American Type Culture Collection (American Type Culture Collection, ATCC®, No. 6475), hereinafter referred to as B16F10 cells.
- 2. Cell culture medium: Basal medium containing 10 vol % FBS (fetal bovine serum, available from Gibco), wherein the basal medium is Eagle's minimum essential medium (MEM) (Gibco, Catalog No. 15188-319) with the addition of 1 mM sodium pyruvate (Gibco), 1.5 g/L sodium bicarbonate (Sigma), and 0.1 mM non-essential amino acid solution (Gibco).
- 3. Phosphate Buffered Saline solution (PBS solution): purchased from Gibco, Catalog No.: 10437-028.
- 4. Kojic acid, purchased from Sigma-Aldrich, product No. K3125-5G.
- 5. Radioimmunoprecipitation protein lysis buffer (RIPA Lysis Buffer (PMSF)): purchased from Sigma-Aldrich, product No. 10837091001.
- 6. Bio-rad Protein Assay, available from Biotek, Item Epoch.
- 7. 10 mM L-dopa: obtained by dissolving 0.8 mg of L-dopa (Sigma-Aldrich, product No. D9628-5G) into 5 mL of 0.1 mM, pH 7.0 PBS.
- 8. Trypsin: 10× Trypsin-EDTA (Gibco) diluted 10-fold in 1×PBS solution.
- 9. Red quinoa extract: prepared by the method detailed in EXAMPLE 1.
- Experimental Procedure:
- Seed 1.5×105 B16F10 cells with 2 mL of medium in each well of a 6-well plate and incubate at 37° C. for 24 hours.
- Then, carefully remove the culture medium without interfering with the attachment of cells.
- This experiment is divided into three groups: the control group, experimental group A, and experimental group B. The control group is added with 2 mL of fresh medium and incubated for 48 hours; experimental group A is added with 2 mL of 1 mg/mL red quinoa extract and incubated for 48 hours; experimental group B is added with 2 mL of 0.5 mg/mL red quinoa extract, and incubated for 48 hours. The red quinoa extract samples in experimental groups A and B were obtained by mixing 2 mL of medium with 14.3 μL and 28.6 μL of the red quinoa extract prepared from EXAMPLE 1.
- Subsequently, the medium is removed and washed with 1×PBS (Gibco) twice. Trypsin-EDTA was added to the wells and to react for 3 minutes. The cells were then retrieved from the suspension and taken into 15 mL centrifuge tubes, where they were centrifuged for 5 minutes at 400×g to pellet the cells.
- Then, the precipitated cells were washed twice with 1×PBS, suspended with 200 μL cell lysate, vortexed, and centrifuged for 20 min at 12,000×g.
- Transfer the supernatant to 1.5 mL centrifuge tubes, where the protein concentrations are detected:
- Bio-rad dye is mixed with deionized water (volume ratio 1:4) and distributed into 7 microcentrifuge tubes, each having 500 μL of the solution. Then, the microcentrifuge tubes were added with 10 μL, 8 μL, 6 μL, 4 μL, 2 μL, 1 μL, and 0 μL of 2 mg/mL BSA, respectively to prepare the standard protein concentration sample. Next, 2 μL of supernatant is added to each microcentrifuge tube for testing. The microcentrifuge tubes were then added to the wells of a 96 well plate where each well is added with 200 μL of protein assay reagent. Then, the absorbance value was measured at 595 nm using the ELISA reader (BioTek).
- Next, 400 μg of protein is added to each well Then, 90 μL cell lysate is added to each well, including the control group. Under a dark environment, add 10 μL, 10 M of L-Dopa at 37° C. and observe the suspension once every 10 minutes, until the suspension turns black. Then, measure the absorbance value at 405 nm.
- Tyrosinase inhibition is calculated with the following formula:
-
Tyrosinase Inhibition (%)=(OD sample/OD control)×100%. - The results are then analyzed with Microsoft EXCEL software using its Student t-test statistical analysis.
- Referring to
FIG. 3 , the tyrosinase inhibition is improved in the group containing the red quinoa extract and increases with the red quinoa extract concentration. Specifically, experimental group B (0.5 mg/mL of red quinoa extract) has a 30.4% higher tyrosine inhibition rate than experimental group A (1 mg/mL of red quinoa extract), which has a 42.6% higher tyrosine inhibition rate than the control group. Thus, the red quinoa extract disclosed herein reduces tyrosinase activity, which, in turn, reduces the formation of melanin. This shows that the red quinoa extract disclosed here can be used to reduce skin spots, improve skin condition, whiten the skin. - This example demonstrates the melanin content reducing capability of the red quinoa extract disclosed herein by quantifying the difference in melanin content after treating B16F10 melanoma cells with the red quinoa extract disclosed herein with ELISA reader (enzyme-linked immunosorbent assay reader).
- Materials and Equipment
-
- 1. Cell line: B16F10 mouse melanoma cells, purchased from American Type Culture Collection (American Type Culture Collection, ATCC®, No. 6475), hereinafter referred to as B16F10 cells.
- 2. Cell culture medium: Basal medium containing 10 vol % PBS (fetal bovine serum, available from Gibco), wherein the basal medium is Eagle's minimum essential medium (MEM) (Gibco, Catalog No. 15188-319) with the addition of 1 mM sodium pyruvate (Gibco), 1.5 g/L sodium bicarbonate (Sigma), and 0.1 mM non-essential amino acid solution (Gibco).
- 3. Phosphate Buffered Saline solution (PBS solution): purchased from Gibco, Catalog No.: 10437-028.
- 4. 1N NaOH (Sigma, Product No. 221465).
- 5. ELISA reader (BioTek, FLx 800).
- 7. Blue Light (wavelength: 400 nm-500 nm).
- 6. Red quinoa extract: prepared from EXAMPLE 1.
- Experimental Procedure
- This experiment is divided into two groups with three replicates: the experimental group and the control group:
-
- 1. Seed 1.5×105 B16F10 cells with 2 mL of medium in each well of a 6-well plate.
- 2. Incubate plate at 37° C. for 24 hours.
- 3. Carefully remove culture medium without interfering with attachment of cells.
- 4. The experimental group is added with 2 mL of 0.5 mg/mL red quinoa extract and incubated for 48 hours. The red quinoa extract sample was obtained by mixing 2 mL of medium with 14.3 μL of the red quinoa extract prepared from EXAMPLE 1.
- The control group is added with 2 mL of fresh medium and incubated for 48 hours.
-
- 5. The experimental group is exposed to blue light at room temperature (25±5° C.) for 3 hours.
- The control group is moved to a dark room and allowed to stand at room temperature for 3 hours.
-
- 6. Next, incubate cells at 37° C. for 48 hours.
- 7. The culture medium is removed and the cells were washed with PBS solution two times.
- 8. 200 μl Trypsin-EDTA (10×) (Gibco; Catalog No. 15400-054) is added to each well for 3 minutes. Then, 6 mL of culture medium is added to terminate the reaction. Collect the suspended cells to a 15 ml centrifuge tube and centrifuge at 400×g for 5 minutes to pellet the cells.
- 9. After washing with PBS twice, resuspended the cells with 200 μL PBS.
- 10. The cell suspension is frozen in liquid nitrogen for 10 minutes and then left at room temperature for about 30 minutes until completely thawed.
- 11. After thawing is complete, the tubes were centrifuged at 12,000 g for 3 minutes.
- 12. After removing the supernatant, use 120 μL of 1N sodium hydroxide solution to precipitate the cells and put the test tube in a hot plate at 60° C. for 1 hour to obtain samples for detection.
- 13. Take 100 μL of the sample into a 96-well plate, and measure optical density at 450 nm with the ELISA reader.
- Experimental Results
- Melanin content of the groups are calculated with the following formula:
-
Melanin Content (%)=(OD450 Experimental/OD450 Control)×100%. - Since the experiment was carried out in triplets, the values were averaged, as shown in
FIG. 4 . - As shown in
FIG. 4 , the melanin content of the experiment group is 29.7% lower than the control group, indicating that the red quinoa extract disclosed herein has can effectively reduce the production of melanin in melanocytes. - This example uses an RNA extraction kit, reverse transcriptase, a KAPA SYBR® FAST qPCR reagent kit, and quantitative PCR to determine the expression of antioxidation-related genes in human skin fibroblasts (CCD-966sk) after being treated by the red quinoa extract disclosed herein.
- Materials and Equipment
-
- 1. Cell line: Human skin fibroblasts CCD-966sk (BCRC No. 60153).
- 2. Cell culture medium: Basal medium containing 10 vol % FBS (fetal bovine serum, available from Gibco), wherein the basal medium is Eagle's minimum essential medium (MEM) (Gibco, Catalog No. 15188-319) with the addition of 1 mM sodium pyruvate (Gibco), 1.5 g/L sodium bicarbonate (Sigma), and 0.1 mM non-essential amino acid solution (Gibco).
- 3. RNA extraction reagent kit (Geneaid, Taiwan, Lot No. FC24015-G).
- 4. Reverse Transcriptase (SuperScript® III Reverse Transcriptase) (Invitrogen Corporation, USA, No. 18080-051).
- 5. Target gene primers: the SOD2 gene and the GAPDH gene (internal control group).
- 6. KAPA SYBR® FAST qPCR reagent set (purchased from Sigma, USA, No. 38220000000)
- 7. AB1 StepOnePlus™ Real-Time PCR system (Thermo Fisher Scientific Inc., USA).
- 8. Red quinoa extract: prepared from EXAMPLE 1.
- Experimental Procedure
- The cell culture experiment process is as follows:
- This experiment is divided into two groups with three replicates: the experimental group and the control group:
-
- 1. Seed 1.5×105 CCD-966sk cells with 2 mL of medium in each well of a 6-well plate and incubate at 37° C. for 16 hours.
- 2. Experimental group: per ml culture broth containing a red-quinoa extract prepared 28.6 μL of a sample obtained by the embodiment (i.e., at a concentration of 1 mg/mL) is prepared to contain extract broth, the CCD-966sk cell extracts containing replaced broth culture is continued.
- 3. The experimental group is added with 2 mL of 1 mg/mL red quinoa extract and incubated for 6 hours. The red quinoa extract sample was obtained by mixing 2 mL of medium with 28.6 μL of the red quinoa extract prepared from EXAMPLE 1.
- The control group is added with 2 mL of fresh medium and incubated for 6 hours
-
- 4. After incubation, lysate the cells of both the experimental and control groups using the reagents provided in the RNA extraction kit.
- The polymerase chain reaction experiment process is as follows:
-
- a. Collect the RNA of the cells in both groups using the RNA extraction kit.
- b. Next, take 2000 nanograms (ng) of the RNA extracted in each group as a template, and use the primers listed in Table 1 to reverse-transcribe cDNA using SuperScript® III reverse transcriptase.
- c. Use the primers in Table 1 to conduct quantitative real-time reverse transcription polymerase chain reaction with StepOnePlus™ Real-Time PCR system and KAPA SYBR FAST. This allows the observation of the gene expression levels of the experimental group and the control group. The parameters for the PCR are 95° C./1 s, 60° C/20 s, 40 loops
- d. The relative gene expression levels are determined by the 2−ΔΔCt method. The “relative gene expression levels” are defined as the fold change of the experimental groups RNA expression level to that of the control group. The GADPH gene is served as the internal control of the reference gene cycle threshold (Ct). Fold change is calculated according to the following formula:
-
ΔCt=Ctexperimental group target gene/control group target gene−CtTBP -
ΔΔCt=ΔCt of experimental group−ΔCt gene of the control group -
Fold change=2−ΔΔCt average -
- 5. Finally, the standard deviation and a one-tailed Student t-test analysis are conducted with Microsoft Excel to determine whether a significant difference exists (* p value<0.05 statistically; ** p value<0.01; *** p value<0.001). The SOD2 gene's corresponding primer is SOD2-F and SOD2-R while the gene corresponding to the GADPH is GADPH-F primers and GADPH-R.
-
TABLE 1 Primer Sequence No. Sequence SOD2-F SEQ ID NO: 1 AGAGTGGACCAACTGAAGAGT SOD2-R SEQ ID NO: 2 ATTCTCTGCATTTGTCCGCTT GADPH-F SEQ ID NO: 3 TCCTACTTGGACAAAGTTCGGG GADPH-R SEQ ID NO: 4 CCCCTGATGTGAGTTGCCA - Experimental Results
-
FIG. 5 . shows the relative expression levels of the antioxidation-related genes of the experiment and control group. - From
FIG. 5 ., the relative expression level of the SOD2 gene in the experimental group is 2725%. In other words, compared with the control group, the expression level of the antioxidation-related SOD2 gene in the experimental group increased 2625%, reaching statistical significance. Thus, the red quinoa extract disclosed herein has free radical scavenging properties and can function as an antioxidant. - This example uses an RNA extraction kit, reverse transcriptase, a KAPA SYBR® FAST qPCR reagent kit, and quantitative PCR to determine the expression of moisture-related genes in human epidermal keratinocytes (HPEK-50) after treatment of the red quinoa extract disclosed herein.
- Materials and Equipment
-
- 1. Keratinocyte serum-free medium (Keratinocyte-SFM; available from Thermo, part number 17005042).
- 2. Human epidermal keratinocytes (hereinafter as HPEK-50 cells or keratinocytes; available from CELLnTEC).
- 3. RNA extraction reagent kit (Geneaid, Taiwan, Lot No. F024015-G).
- 4. Reverse Transcriptase (SuperScript® III Reverse Transcriptase) (Invitrogen Corporation, USA, No. 18080-051).
- 5. Target gene primers: the TGM1 gene, the KRT1 gene, the KRT10 gene, and the TBP gene (internal control group).
- 6. KAPA SYBR® FAST qPCR reagent set (purchased from Sigma, USA, No. 38220000000)
- 7. ABI StepOnePlus™ Real-Time PCR system (Thermo Fisher Scientific Inc., USA).
- 8. Red quinoa extract, prepared from EXAMPLE 1.
- Experimental Procedure
- The cell culture experiment process is as follows:
- This experiment is divided into two groups with three replicates: the experimental group and the control group:
-
- 1. Seed 1.5×105 HPEK-50 cells with 2 mL of medium in each well of a 6-well plate and incubate at 37° C. for 16 hours.
- 2. The experimental group is added with 2 mL of 2 mg/mL red quinoa extract, and incubated for 6 hours. The red quinoa extract sample was obtained by mixing 2 mL of medium with 57.2 μL μL of the red quinoa extract prepared from EXAMPLE 1.
- The control group is added with 2 mL of fresh medium and incubated for 6 hours
-
- 3. After incubation, lysate the cells of both the experimental and control groups using the reagents provided in the RNA extraction kit.
- 4. The polymerase chain reaction experiment process is as follows:
- a. Collect the RNA of the cells in both groups using the RN A extraction kit.
- b. Next, take 2000 nanograms (ng) of the RNA extracted in each group a template, and use the printers listed in Table 1 to reverse transcribe cDNA using SuperScript® III reverse transcriptase.
- c. Use the primers in Table 2 to conduct quantitative real-time reverse transcription polymerase chain reaction with StepOnePlus™ Real-Time PCR system and KAPA SYBR FAST. This allows the observation of the gene expression levels of the experimental group and the control group. The parameters for the PCR are: 95° C./1 s, 60° C./20 s, 40 loops
- d. The relative gene expression levels are determined by the 2−ΔΔCt method. The “relative gene expression levels” are defined as the fold change of the experimental group's RNA expression level to that of the control group. The TBP gene is served as the internal control of the reference gene cycle threshold (Ct). Fold change is calculated according to the following formula:
-
ΔCt=Ctexperimental group target gene/control group target gene−CtTBP -
ΔΔCt=ΔCt of experimental group−ΔCt gene of the control group -
Fold change=2−ΔΔCt average - 5. Finally, the standard deviation and a one-tailed Student t-test analysis is conducted with Microsoft Excel to determine whether a significant difference exists (* p value<0.05 statistically; ** p value<0.01; *** p value<0.001). The TGM1 gene's corresponding primer pair is TGM1-F and TGM1-R, the KRT1 gene's corresponding primer pair is KRT1-F and KRT1-R, the KRT10 gene's corresponding primer pair is KRT10-F and KRT10-R, the TBP gene's corresponding primer pair is TBP-F and TBP-R.
-
TABLE 2 Primer Sequence No. Sequence TGM1-F SEQ ID NO: 5 GATCGCATCACCCTTGAGTTAC TGM1-R SEQ ID NO: 6 GCAGGTTCAGATTCTGCCC KRT1-F SEQ ID NO: 7 AGAGTGGACCAACTGAAGAGT KRT1-R SEQ ID NO: 8 ATTCTCTGCATTTGTCCGCTT KRT10-F SEQ ID NO: 9 TATACTTGGACAAAGTTCGGG KRT10-R SEQ ID NO: 10 CCCCTGATGTGAGTTGCCA TBP-F SEQ ID NO: 11 TATAATCCCAAGCGCTTTTGC TBP-R SEQ ID NO: 12 GCTGGAAAACCCAACTTCTG - Experimental Results
-
FIG. 6 . shows the relative expression levels of the moisture-related genes of the experiment and control group. - From
FIG. 5 , the relative expression levels of the TGM1 gene, the KRT1 gene, and the KRT10 gene are 234%, 432% and 435%, respectively. In other words, compared with the control group, the expression level of the TGM1 gene, the KRT1 gene, and the KRT10 gene in the experimental group increased 134%, 332%, and 335%, respectively, all reaching statistical significance. Thus, the red quinoa extract disclosed herein can prevent skin water loss, moisturize the skin and improve skin function. - This example demonstrates the antioxidation and skin condition, improving properties of the red quinoa extract disclosed herein by administering drinks containing the red quinoa extract disclosed in the present invention to human subjects.
- Drinking Sample: Beverage containing the presently disclosed red quinoa extract 50 g/bottle, which comprises: red quinoa extracted 10 wt %, apple juice concentrate 6 wt %,
fructose 6 wt %, 0.4 wt % citrus pectin, citric acid 0.2 wt %, apple liquid spices 0.24 wt %, water 77.16 wt %. In other embodiments, the intake of red quinoa extract can be up to 10 g/day. The red quinoa extract herein is produced with the method detailed in EXAMPLE 1. It should be noted that theconcentrated apple juice 6 wt %,fructose 6 wt %, citrus pectin 0.4 wt %, citric acid 0.2 wt %, apple liquid spices 0.24 wt % are meant to flavor and to enhance the shelf life of the beverage. - Number of subjects: 30 subjects, 30-55 years of age.
- Experimental Procedure
-
- 1. Collect 30 subjects. Before dunking the beverages, the subjects' skin conditions (face cleaned, week 0) using the corresponding instruments. Blood samples of the subjects were also collected (under fasting conditions) to measure the content of antioxidant enzymes in the body.
- 2. Next, randomly select 15 subjects as the placebo group and the remaining 15 as the experimental group. The experimental group bikes a bottle of the beverage daily (containing 5 g of red quinoa extract) for a total of 56 days (i.e., 8 weeks). The placebo group takes placebo beverages (same content as the beverage drunk by the experimental group only that the 5 g red quinoa extract was substituted with an equal amount of water).
- 3. The skin conditions of the subjects in the placebo group and the experimental groups were measured at
week 0,week 4, andweek 8. Their blood samples were also collected atweek 0,week 4, andweek 8. It should be noted that the temperature, humidity, and other environmental factors of where the measurements took place were the same atweek 0,week 4,week 8 so as to reduce the impact of other factors on the skin condition measurements. Moreover, during the clinical trial, the subjects' diets and lifestyles were unchanged so as to reduce other factors that may impact the content of in vivo antioxidants.
- Measurements
- 1. Skin Hydration, 2. Skin color, 3. Skin texture, 4 Crow's feet, 5. Antioxidant Enzyme Content
- 1. Skin Hydration
- Purchased from the German company Courage+Khazaka electronic, the skin hydration probe Corneometer® CM825 (C+K MμLti Probe Adapter System, Germany) is used to detect facial skin hydration in both groups. The values of the detection probe are based on capacitive measurement. Since the capacitance value of the skin changes with the skin's hydration, the detection probe can analyze skin hydration by measuring skin capacitance values.
- 2. Skin Color
- Purchased from the Irish company Miravex, the 3D analytical lens of Antera 3D is used to detect facial skin color in both groups. The instrument first emits lights using its LED (light-emitting diodes) at different wavelengths and angles and then collects the reflected lights that bounce off of the skin to analyze the skin color. Antera uses colorimeter to analyze color, which depends on the parameters L*a*b* in which L* refers to brightness: the a* axis represents the green-red component, with green in the negative direction and red in the positive direction; the b* axis represents the blue-yellow component, with blue in the negative direction and yellow in the positive direction.
- For the difference (ΔE*ab) color 1 (L*1, a*1, b*1) and color 2 (L*2, a*2, b*2) can be calculated by the following formula:
-
ΔE* ab=√{square root over ((L* 2 −L* 1)2+(a* 2 −a* 1)2+(b* 2 −b* 1)2)} - Since this example mainly concerns the whitening of the skin, only the L* value is observed and recorded. The higher the L* value is, the brighter and hence the whiter the skin is.
- 3. Skin Texture
- Skin texture is measured using the VISIA Digital Skin Detector (Canfield, US). The instrument uses visible light to capture high-resolution images of the skin and uses its built-in software to analyze skin roughness. The higher the measured value is, the rougher the skin is.
- 4. Crow's Feet Measurement
- The Soft Plus Skin Detector (Callegari 1930) is used to measure the end of the subjects' eyes to evaluate crow's feet. The instrument detects the area of shades against standard light to quantify the depth of crow's feet.
- 5. Antioxidant Enzymes Measurement
- First, the collected blood samples were transferred into a centrifuge tube and centrifuged at 700-1000×g, 4° C. for 10 minutes. After centrifugation, the upper plasma layer is removed, and 2 mL of the blood cell layer (i.e., buffy coat) is placed in another centrifuge tube where 2 mL of PBS is added and mixed to provide a diluted buffy coat.
- Add 3 mL of the diluted buffy coat into another test tube and slowly add Ficoll-Plague Plus solution (Sigma), and then centrifuged at a rotational speed of 400 g for 40 minutes. After centrifugation, remove the supernatant liquid and
transfer 2 mL-3 mL of the intermediate layer (i.e., the mononuclear cell layer) to a new centrifuge tube. - After washing the mononuclear cells with
PBS 3 to 5 times, centrifuge it for 10 minutes with 300 g. After centrifugation, the supernatant is the sample used for subsequent experiments. - Reference to the instructions provided by the Cayman Catalase Assay Kit No. 707002 (https://www.caymanchem.com/pdfs/707002.pdf). A summarized procedure is presented as follows:
-
Mix 10 μL of the standardized hydrogen peroxide formaldehyde enzyme (Cayman, No. 707014) with a buffer solution of 9.99 mL to obtain a formaldehyde solution of 4.25 mM. Take 7 tubes and label them from A through G and formulate them according to Table 3 to give the standard solutions: -
TABLE 3 Test Formaldehyde Buffer Solution Final Formaldehyde Tube (μL) (μL) Concentration (μM) A 0 1000 0 B 10 990 5 C 30 970 15 D 60 940 30 E 90 910 45 F 120 880 60 G 150 850 75 - This experiment is divided into three groups: the standard formaldehyde group, the positive control group, and the experimental group. The standard formaldehyde group takes up seven wells, wherein each well contains 100 μL of buffer solution, 30 L of methanol, and 20 μL of the standard solution (tube A to G); the positive control group takes up two wells, wherein each well contains 100 μL of buffer solution, 30 L of methanol, and 20 μL of the diluted antioxidant enzymes; while the experimental group wells contain 100 μL of buffer solution, 30 μL of methanol and 20 μL of the experimental samples (i.e., the processed blood samples).
- Add 20 μL of hydrogen peroxide to each well to start the reaction, and then the wells were shaken at room temperature for 10 minutes.
- Next, 30 μL of potassium hydroxide is added to terminate the reaction, and a 30 μL of dye (Catalase Purpalf, Cayman No. 707017) is added to each well. The wells were then shaken at room temperature for 10 minutes.
- Then, add 10 μL Catalase Potassium Periodate (Cayman No. 707017) and shake wells at room temperature after 5 minutes.
- Finally, read the absorbance values at 540 nm wavelength.
- Catalase Content is calculated as follows:
- First, subtract the absorbance values of each sample with the absorbance value of standard solution A and then plot the subtracted values. The y-axis is the absorbance value (540 nm), while the x-axis is the concentration of formaldehyde (μM). The calculation of the formaldehyde concentration of the experimental group of:
-
Formaldehyde concentration (μM)=((absorbance value of experimental group−y-intercept of the drawing made)/slope of the drawing made)*(0.17 mL/0.02 mL) - Then calculate the enzyme activity of catalase:
-
Catalase activity=(sample formaldehyde concentration (μM))/(20 min)×dilution ratio experiment=nmol/min/mL - The catalase content is set at 100% at
week 0 for both the placebo and control group to better present the relative catalase content of the groups. -
FIG. 7 . shows the average skin hydration percentage atweek 0,week 4, andweek 8 of the placebo group and the experiment group. Atweek 4, 93% of the subjects had an increase in skin hydration, whereas, atweek week 4 andweek 8 were also higher than those of the placebo group inweek 4 andweek 8 by 5.1% and 6.6%, respectively. Thus, the present disclosed red quinoa extract can be used to moisturize the skin and maintain skin moisture retention. -
FIG. 8 . shows the average skin color percentage atweek 0,week 4, andweek 8 of the placebo group and the experiment group. Atweek 4, 93% of the subjects had an increase in skin color, whereas, atweek week 4 andweek 8 were also higher than those of the placebo group inweek 4 andweek 8 by 3.6% and 4.1%, respectively. Thus, the present disclosed red quinoa extract can be used to brighten and whiten skin color. -
FIG. 9 . shows the average skin texture percentage atweek 0,week 4, andweek 8 of the placebo group and the experiment group. Atweek 4, 73% of the subjects had an increase in skin texture, whereas, atweek 8, 83% of the subjects had an increase in skin texture. When the test subjects' average skin texture percentage before beverage consumption is 100%, the average skin texture percentage after 4 weeks of consumption is 91.1%, while the average skin texture percentage after 8 weeks of consumption is 90.2%. In other words, the subjects in the experimental group had an average decrease of 8.9% and 9.8% in skin texture, respectively. The average skin texture percentages of the experiment group inweek 4 andweek 8 were also lower than those of the placebo group inweek 4 andweek 8 by 10.6% and 18.1%, respectively. Thus, the present disclosed red quinoa extract can be used to improve skin texture and reduce the roughness of the skin -
FIG. 10 . shows the average crow's feet percentage atweek 0,week 4, andweek 8 of the placebo group and the experiment group. At bothweek 4 andweek week 4 andweek 8 were also lower than those of the placebo group inweek 4 andweek 8 by 9.9% and 8.9%, respectively. Thus, the present disclosed red quinoa extract can be used to soothe wrinkles -
FIG. 11 . shows the average in vivo antioxidant enzyme (catalase) percentage atweek 0,week 4, andweek 8 of the placebo group and the experiment group. Atweek week 8 were also higher than those of the placebo group inweek 8 by 183.7%. Thus, the present disclosed red quinoa extract can lie used to enhance the content of antioxidant enzymes, thereby achieving antioxidative properties in vivo. - Although the present invention has been described in considerable detail with reference to certain preferred embodiments thereof, the disclosure is not for limiting the scope of the invention. Persons having ordinary skill in the art may make various modifications and changes without departing from the scope and spirit of the invention. Therefore, the scope of the appended claims should not be limited to the description of the preferred embodiments described above.
Claims (18)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/095,763 US20210137826A1 (en) | 2019-11-12 | 2020-11-12 | Use of chenopodium formosanum (djulis) extract for antioxidation and improving skin appearance |
US18/063,694 US20230240974A1 (en) | 2019-11-12 | 2022-12-09 | Method for skin brightening using chenopodium formosanum (djulis) extract |
US18/185,409 US20230263722A1 (en) | 2019-11-12 | 2023-03-17 | Method for scavenging free radicals in cell using chenopodium formosanum (djulis) extract |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962934014P | 2019-11-12 | 2019-11-12 | |
US17/095,763 US20210137826A1 (en) | 2019-11-12 | 2020-11-12 | Use of chenopodium formosanum (djulis) extract for antioxidation and improving skin appearance |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/063,694 Continuation US20230240974A1 (en) | 2019-11-12 | 2022-12-09 | Method for skin brightening using chenopodium formosanum (djulis) extract |
US18/185,409 Division US20230263722A1 (en) | 2019-11-12 | 2023-03-17 | Method for scavenging free radicals in cell using chenopodium formosanum (djulis) extract |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210137826A1 true US20210137826A1 (en) | 2021-05-13 |
Family
ID=75847435
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/095,763 Abandoned US20210137826A1 (en) | 2019-11-12 | 2020-11-12 | Use of chenopodium formosanum (djulis) extract for antioxidation and improving skin appearance |
US18/063,694 Pending US20230240974A1 (en) | 2019-11-12 | 2022-12-09 | Method for skin brightening using chenopodium formosanum (djulis) extract |
US18/185,409 Pending US20230263722A1 (en) | 2019-11-12 | 2023-03-17 | Method for scavenging free radicals in cell using chenopodium formosanum (djulis) extract |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/063,694 Pending US20230240974A1 (en) | 2019-11-12 | 2022-12-09 | Method for skin brightening using chenopodium formosanum (djulis) extract |
US18/185,409 Pending US20230263722A1 (en) | 2019-11-12 | 2023-03-17 | Method for scavenging free radicals in cell using chenopodium formosanum (djulis) extract |
Country Status (3)
Country | Link |
---|---|
US (3) | US20210137826A1 (en) |
CN (4) | CN112843097A (en) |
TW (4) | TWI801770B (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150157644A1 (en) * | 2013-12-06 | 2015-06-11 | Rutgers, The State University Of New Jersey | Methods of making quinoa leachates and uses thereof |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1535717A (en) * | 2003-04-11 | 2004-10-13 | 成都地奥制药集团有限公司 | Chinese medicine clove and application of its extract in preparation of medicine for reducing weight |
JP2006076954A (en) * | 2004-09-10 | 2006-03-23 | Mercian Corp | Antiobestic agent, blood cholesterol level elevation inhibitor, and food and drink |
CN101088317B (en) * | 2007-07-11 | 2010-11-17 | 中国科学院水生生物研究所 | Proliferation process of wild common nostoc resource |
CN101376871A (en) * | 2007-08-31 | 2009-03-04 | 沈阳科健生物技术有限公司 | Preparation of raspberry fruit vinegar |
TW201102108A (en) * | 2009-07-15 | 2011-01-16 | Univ Nat Pingtung Sci & Tech | A natural facial-cleaning component |
CN101647759B (en) * | 2009-09-08 | 2011-09-07 | 武汉大学 | Application of nostoc polysaccharide in nutritional humidity-preserving type cosmetic |
CN101822630A (en) * | 2010-03-24 | 2010-09-08 | 湖南炎帝生物工程有限公司 | Nostoc sphaeroids kutz extractive and application thereof in cosmetics |
KR20120120736A (en) * | 2011-04-25 | 2012-11-02 | 영남대학교 산학협력단 | Composition Comprising Extract of Clove for Prevention and Ttreatment of Metabolic Syndrome |
CN103432266B (en) * | 2013-07-29 | 2014-11-05 | 高兴华 | External ointment for treating burns and scalds |
TWI516280B (en) * | 2014-03-20 | 2016-01-11 | 大江生醫股份有限公司 | Use of chenopodium formosanum extract for manufacture of composition for enhancing secretion of collagen and preventing cutaneous aging |
CN104026447B (en) * | 2014-05-15 | 2016-03-09 | 安徽禾木食品有限公司 | The fragrant Nutritive Rice of a kind of coconut palm and processing method thereof |
KR20160001935A (en) * | 2014-06-30 | 2016-01-07 | 원광대학교산학협력단 | A composition comprising the extract of black current for preventing, improving or treating metabolic syndrome |
TWI632919B (en) * | 2016-05-05 | 2018-08-21 | 臺鹽實業股份有限公司 | Crude extract of red djulis with anti-skin wrinkling activity, method of making the same and applications thereof |
TWI691340B (en) * | 2017-05-11 | 2020-04-21 | 嘉藥學校財團法人嘉南藥理大學 | Red quinoa extract with anti-aging, whitening, anti-allergy and cell repair |
CN110037950B (en) * | 2018-01-15 | 2022-02-25 | 大江生医股份有限公司 | Use of coffee cherry pulp extract |
CN110051572B (en) * | 2018-01-19 | 2022-03-15 | 百岳特生物科技(上海)有限公司 | Pomegranate fermentation product and use thereof |
CN110419742A (en) * | 2018-08-07 | 2019-11-08 | 湖南炎帝生物工程有限公司 | Nostoc composition and its application in adjusting blood lipid, prevention and/or treatment atherosclerosis |
CN109984338A (en) * | 2019-05-09 | 2019-07-09 | 青岛浩然海洋科技有限公司 | A kind of production method of natural astaxanthin and nostoc complex tablet |
-
2020
- 2020-11-11 CN CN202011252120.2A patent/CN112843097A/en active Pending
- 2020-11-11 TW TW109139410A patent/TWI801770B/en active
- 2020-11-12 CN CN202011261214.6A patent/CN112843139A/en active Pending
- 2020-11-12 CN CN202011259619.6A patent/CN112843136A/en active Pending
- 2020-11-12 TW TW109139602A patent/TWI804771B/en active
- 2020-11-12 TW TW109139603A patent/TWI815058B/en active
- 2020-11-12 CN CN202011259618.1A patent/CN112843106A/en not_active Withdrawn
- 2020-11-12 US US17/095,763 patent/US20210137826A1/en not_active Abandoned
- 2020-11-12 TW TW109139601A patent/TWI809328B/en active
-
2022
- 2022-12-09 US US18/063,694 patent/US20230240974A1/en active Pending
-
2023
- 2023-03-17 US US18/185,409 patent/US20230263722A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150157644A1 (en) * | 2013-12-06 | 2015-06-11 | Rutgers, The State University Of New Jersey | Methods of making quinoa leachates and uses thereof |
Non-Patent Citations (1)
Title |
---|
Hong et al. (2016) Biomed Research International, Volume 2016, Article 7368797 (8 pages) (Year: 2016) * |
Also Published As
Publication number | Publication date |
---|---|
TWI809328B (en) | 2023-07-21 |
CN112843097A (en) | 2021-05-28 |
TW202118481A (en) | 2021-05-16 |
TWI801770B (en) | 2023-05-11 |
CN112843136A (en) | 2021-05-28 |
TWI804771B (en) | 2023-06-11 |
CN112843106A (en) | 2021-05-28 |
US20230240974A1 (en) | 2023-08-03 |
US20230263722A1 (en) | 2023-08-24 |
TW202118501A (en) | 2021-05-16 |
CN112843139A (en) | 2021-05-28 |
TW202118502A (en) | 2021-05-16 |
TW202118505A (en) | 2021-05-16 |
TWI815058B (en) | 2023-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Goñi et al. | By-products from plant foods are sources of dietary fibre and antioxidants | |
CN114099586B (en) | Application of muskmelon eggplant fermentation juice | |
US20210137826A1 (en) | Use of chenopodium formosanum (djulis) extract for antioxidation and improving skin appearance | |
CN112237284A (en) | Application of wild cherry juice in inhibiting skin aging | |
CN113116770B (en) | Use of pineapple Sakya juice in cosmetic composition for improving skin condition | |
JP2005220100A (en) | Anti-ageing agent, platelet aggregation inhibitor, antioxidant, anti-allergic agent, skin cosmetic, and food and drink | |
TWI815071B (en) | Uses of euterpe oleracea ferment for inhibiting the activity of amylase, promoting lipid metabolism and slowing the aging process | |
TWI813400B (en) | Use of versailles gooseberry extract for improving skin condition | |
CN112842956B (en) | Application of Cymbopogon citratus to conditioning skin | |
TWI834368B (en) | Uses of white bayberry extract for resisting aging or reducing fat | |
CN215873329U (en) | Multi-layer grain structure of nutrition composition for promoting skin cell activation and resisting oxidation | |
TWI820566B (en) | Uses of plums extract in preparing composition for promoting metabolism | |
TWI820448B (en) | Use of rubus fruticosus extract for manufacturing a skincare composition | |
TWI835432B (en) | USE OF LONGAN FLOWER EXTRACT FOR INHIBITION OF β-GALACTOSIDASE ACTIVITY OF STEM CELL AND PROMOTING SKIN HEALTH | |
TWI754345B (en) | Use of garcinia mangostana fermented liquid for preparing a composition for beautifying skin and/or reducing fat | |
KR101610737B1 (en) | Method for preparing Vinegar added with the Fruit of Akebia quinata having anti-oxidative, Vinegar manufactured by this method, and the functional foodcomposition comprising the same | |
KR102087292B1 (en) | Red ginseng soymilk and manufacturing method thereof | |
CN118141714A (en) | Application of kiwi berry extract in resisting skin aging | |
KR20230029186A (en) | Apple puree containing peel added vitamin C and preparing method thereof | |
TW202402316A (en) | Uses ofprunus lannesianaextract on improving skin condition and promoting basal metabolic rate | |
CN115990124A (en) | Use of passion fruit ferment for improving skin state and resisting photoaging | |
CN116426408A (en) | Use of lactobacillus sake or its metabolites for the production of spermidine | |
WO2014003352A1 (en) | Composition containing immature fructus extract of rubus coreanus miquel as active ingredient for improving blood circulation | |
KR20160051914A (en) | Hypoglycemic compositions comprising extracts of rice wine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: TCI CO., LTD., TAIWAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LIN, YUNG-HSIANG;LI, ZIH-YI;REEL/FRAME:054342/0702 Effective date: 20201110 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |